﻿<?xml version="1.0" encoding="utf-8"?>
<Return xmlns="http://www.irs.gov/efile" xsi:schemaLocation="http://www.irs.gov/efile" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" returnVersion="2016v3.1">
  <ReturnHeader binaryAttachmentCnt="0">
    <ReturnTs>2017-12-20T10:09:44-06:00</ReturnTs>
    <TaxPeriodEndDt>2017-06-30</TaxPeriodEndDt>
    <PreparerFirmGrp>
      <PreparerFirmName>
        <BusinessNameLine1Txt>KPMG LLP</BusinessNameLine1Txt>
      </PreparerFirmName>
      <PreparerUSAddress>
        <AddressLine1Txt>345 PARK AVE</AddressLine1Txt>
        <CityNm>NEW YORK</CityNm>
        <StateAbbreviationCd>NY</StateAbbreviationCd>
        <ZIPCd>10154</ZIPCd>
      </PreparerUSAddress>
    </PreparerFirmGrp>
    <ReturnTypeCd>990</ReturnTypeCd>
    <TaxPeriodBeginDt>2016-07-01</TaxPeriodBeginDt>
    <Filer>
      <EIN>231907729</EIN>
      <BusinessName>
        <BusinessNameLine1Txt>JDRF INTERNATIONAL</BusinessNameLine1Txt>
      </BusinessName>
      <InCareOfNm>% GARY CURTO C/O JDRF INT</InCareOfNm>
      <BusinessNameControlTxt>JDRF</BusinessNameControlTxt>
      <PhoneNum>2127859500</PhoneNum>
      <USAddress>
        <AddressLine1Txt>26 BROADWAY 15TH FL</AddressLine1Txt>
        <CityNm>NEW YORK</CityNm>
        <StateAbbreviationCd>NY</StateAbbreviationCd>
        <ZIPCd>10004</ZIPCd>
      </USAddress>
    </Filer>
    <BusinessOfficerGrp>
      <PersonNm>MARK GREENE</PersonNm>
      <PersonTitleTxt>CFO</PersonTitleTxt>
      <PhoneNum>6468734311</PhoneNum>
      <SignatureDt>2017-12-20</SignatureDt>
      <DiscussWithPaidPreparerInd>true</DiscussWithPaidPreparerInd>
    </BusinessOfficerGrp>
    <PreparerPersonGrp>
      <PreparerPersonNm>DEVIN L DUNCAN</PreparerPersonNm>
      <PTIN>P01249521</PTIN>
      <PhoneNum>2127859700</PhoneNum>
      <PreparationDt>2017-12-18</PreparationDt>
    </PreparerPersonGrp>
    <FilingSecurityInformation>
      <IPAddress>
        <IPv4AddressTxt>167.68.102.5</IPv4AddressTxt>
      </IPAddress>
      <FederalOriginalSubmissionId>20543020173545000000</FederalOriginalSubmissionId>
      <FederalOriginalSubmissionIdDt>2017-12-20</FederalOriginalSubmissionIdDt>
      <FilingLicenseTypeCd>P</FilingLicenseTypeCd>
      <AtSubmissionCreationDeviceId>E665B3E7A8D0C3A51E67724EBAB5121B0EE8EB14</AtSubmissionCreationDeviceId>
      <AtSubmissionFilingDeviceId>BBEE8D8720ADAD65542A46A6E57F18F679A29BCD</AtSubmissionFilingDeviceId>
    </FilingSecurityInformation>
    <TaxYr>2016</TaxYr>
    <BuildTS>2018-03-14 21:41:22Z</BuildTS>
  </ReturnHeader>
  <ReturnData documentCnt="12">
    <IRS990 documentId="IRS990" referenceDocumentId="IRS990ScheduleO">
      <PrincipalOfficerNm>DEREK RAPP</PrincipalOfficerNm>
      <USAddress>
        <AddressLine1Txt>26 BROADWAY 14TH FLOOR</AddressLine1Txt>
        <CityNm>NEW YORK</CityNm>
        <StateAbbreviationCd>NY</StateAbbreviationCd>
        <ZIPCd>10004</ZIPCd>
      </USAddress>
      <GrossReceiptsAmt>230050266</GrossReceiptsAmt>
      <GroupReturnForAffiliatesInd>false</GroupReturnForAffiliatesInd>
      <Organization501c3Ind>X</Organization501c3Ind>
      <WebsiteAddressTxt>www.jdrf.org</WebsiteAddressTxt>
      <TypeOfOrganizationCorpInd>X</TypeOfOrganizationCorpInd>
      <FormationYr>1970</FormationYr>
      <LegalDomicileStateCd>PA</LegalDomicileStateCd>
      <ActivityOrMissionDesc>Accelerating life-changing breakthroughs to cure, prevent and treat Type 1 Diabetes and its complications. SEE SCHEDULE O</ActivityOrMissionDesc>
      <VotingMembersGoverningBodyCnt>33</VotingMembersGoverningBodyCnt>
      <VotingMembersIndependentCnt>31</VotingMembersIndependentCnt>
      <TotalEmployeeCnt>886</TotalEmployeeCnt>
      <TotalVolunteersCnt>300000</TotalVolunteersCnt>
      <TotalGrossUBIAmt>45150</TotalGrossUBIAmt>
      <NetUnrelatedBusTxblIncmAmt>33150</NetUnrelatedBusTxblIncmAmt>
      <PYContributionsGrantsAmt>196804267</PYContributionsGrantsAmt>
      <CYContributionsGrantsAmt>199896852</CYContributionsGrantsAmt>
      <PYProgramServiceRevenueAmt>0</PYProgramServiceRevenueAmt>
      <CYProgramServiceRevenueAmt>0</CYProgramServiceRevenueAmt>
      <PYInvestmentIncomeAmt>6524427</PYInvestmentIncomeAmt>
      <CYInvestmentIncomeAmt>1227269</CYInvestmentIncomeAmt>
      <PYOtherRevenueAmt>1027088</PYOtherRevenueAmt>
      <CYOtherRevenueAmt>1129676</CYOtherRevenueAmt>
      <PYTotalRevenueAmt>204355782</PYTotalRevenueAmt>
      <CYTotalRevenueAmt>202253797</CYTotalRevenueAmt>
      <PYGrantsAndSimilarPaidAmt>75084432</PYGrantsAndSimilarPaidAmt>
      <CYGrantsAndSimilarPaidAmt>79009656</CYGrantsAndSimilarPaidAmt>
      <PYBenefitsPaidToMembersAmt>0</PYBenefitsPaidToMembersAmt>
      <CYBenefitsPaidToMembersAmt>0</CYBenefitsPaidToMembersAmt>
      <PYSalariesCompEmpBnftPaidAmt>74149309</PYSalariesCompEmpBnftPaidAmt>
      <CYSalariesCompEmpBnftPaidAmt>75347284</CYSalariesCompEmpBnftPaidAmt>
      <PYTotalProfFndrsngExpnsAmt>0</PYTotalProfFndrsngExpnsAmt>
      <CYTotalProfFndrsngExpnsAmt>0</CYTotalProfFndrsngExpnsAmt>
      <CYTotalFundraisingExpenseAmt>25764003</CYTotalFundraisingExpenseAmt>
      <PYOtherExpensesAmt>40245664</PYOtherExpensesAmt>
      <CYOtherExpensesAmt>39432392</CYOtherExpensesAmt>
      <PYTotalExpensesAmt>189479405</PYTotalExpensesAmt>
      <CYTotalExpensesAmt>193789332</CYTotalExpensesAmt>
      <PYRevenuesLessExpensesAmt>14876377</PYRevenuesLessExpensesAmt>
      <CYRevenuesLessExpensesAmt>8464465</CYRevenuesLessExpensesAmt>
      <TotalAssetsBOYAmt>197093128</TotalAssetsBOYAmt>
      <TotalAssetsEOYAmt>198753573</TotalAssetsEOYAmt>
      <TotalLiabilitiesBOYAmt>133197854</TotalLiabilitiesBOYAmt>
      <TotalLiabilitiesEOYAmt>121385069</TotalLiabilitiesEOYAmt>
      <NetAssetsOrFundBalancesBOYAmt>63895274</NetAssetsOrFundBalancesBOYAmt>
      <NetAssetsOrFundBalancesEOYAmt>77368504</NetAssetsOrFundBalancesEOYAmt>
      <InfoInScheduleOPartIIIInd>X</InfoInScheduleOPartIIIInd>
      <MissionDesc>JDRFs mission is to accelerate life-changing breakthroughs to cure, prevent and treat Type 1 Diabetes (T1D) and its complications. JDRF is the leading global organization focused on T1D research and is committed to funding the development of new therapies and treatments to keep people with T1D healthier, longer, until a cure is found. Its strength lies in its exclusive focus and singular influence on the worldwide effort to end T1D. JDRF works every day to change the reality of this life-threatening autoimmune disease for millions of people - and to prevent anyone else from contracting the disease - by funding research, advocating for government support of research and new therapies, ensuring new therapies and technologies come to market, and connecting and engaging the T1D community. JDRF has funded more than $2 billion in research to date and made significant progress in understanding and fighting the disease. JDRF has played a role in nearly every T1D therapeutic advance of the past</MissionDesc>
      <SignificantNewProgramSrvcInd>false</SignificantNewProgramSrvcInd>
      <SignificantChangeInd>false</SignificantChangeInd>
      <ExpenseAmt>79009656</ExpenseAmt>
      <GrantAmt>79009656</GrantAmt>
      <Desc>RESEARCH FUNDING FOR THE FY17 PERIOD ENDING JUNE 30, 2017, JDRF DIRECTLY FUNDED RESEARCH GRANTS AND INDUSTRY AGREEMENTS FOR WHICH $79 MILLION IN RESEARCH GRANT NET EXPENSE WAS RECOGNIZED ACCORDING TO GAAP AND EXCLUDING $7.1 MILLION OF PROGRAMMATIC RESEARCH INVESTMENTS WHICH ARE RECORDED TO THE ORGANIZATIONS BALANCE SHEET. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO DIRECT RESEARCH FUNDING. SEE SCHEDULE O.</Desc>
      <ProgSrvcAccomActy2Grp>
        <ExpenseAmt>20866569</ExpenseAmt>
        <Desc>RESEARCH SUPPORT JDRF MAINTAINS AN IN-HOUSE TEAM OF SKILLED SCIENTIFIC, MEDICAL, POLICY AND GOVERNMENT RELATIONS PROFESSIONALS WHO PLAY A CRITICAL ROLE IN LEADING AND SUPPORTING THE EVALUATION OF RESEARCH FUNDING OPPORTUNITIES BY JDRF AND INFLUENCING RESEARCH DIRECTION AND THE DISBURSEMENT OF RESEARCH FUNDS FROM OTHERS. THESE PROFESSIONALS ALSO WORK WITH REGULATORY AND POLICY OFFICIALS TO ENSURE THAT RESEARCH CAN PROCEED WITHOUT DELAY AND RESULTS ARE UNDERSTOOD BY HEALTHCARE DECISION MAKERS. SEE SCHEDULE O.</Desc>
      </ProgSrvcAccomActy2Grp>
      <ProgSrvcAccomActy3Grp>
        <ExpenseAmt>52763561</ExpenseAmt>
        <Desc>PUBLIC EDUCATION AND OUTREACH JDRF EDUCATES THE COMMUNITY AND PROVIDES OUTREACH SERVICES TO NEWLY DIAGNOSED CHILDREN AND ADULTS, THEIR FAMILIES AND OTHERS ABOUT T1D AND ITS COMPLICATIONS. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO PUBLIC EDUCATION AND OUTREACH. SEE SCHEDULE O.</Desc>
      </ProgSrvcAccomActy3Grp>
      <TotalProgramServiceExpensesAmt>152639786</TotalProgramServiceExpensesAmt>
      <DescribedInSection501c3Ind referenceDocumentId="IRS990ScheduleA">true</DescribedInSection501c3Ind>
      <ScheduleBRequiredInd>false</ScheduleBRequiredInd>
      <PoliticalCampaignActyInd referenceDocumentId="IRS990ScheduleC">false</PoliticalCampaignActyInd>
      <LobbyingActivitiesInd referenceDocumentId="IRS990ScheduleC">true</LobbyingActivitiesInd>
      <SubjectToProxyTaxInd referenceDocumentId="IRS990ScheduleC">false</SubjectToProxyTaxInd>
      <DonorAdvisedFundInd referenceDocumentId="IRS990ScheduleD">false</DonorAdvisedFundInd>
      <ConservationEasementsInd referenceDocumentId="IRS990ScheduleD">false</ConservationEasementsInd>
      <CollectionsOfArtInd referenceDocumentId="IRS990ScheduleD">false</CollectionsOfArtInd>
      <CreditCounselingInd referenceDocumentId="IRS990ScheduleD">false</CreditCounselingInd>
      <TempOrPermanentEndowmentsInd referenceDocumentId="IRS990ScheduleD">true</TempOrPermanentEndowmentsInd>
      <ReportLandBuildingEquipmentInd referenceDocumentId="IRS990ScheduleD">true</ReportLandBuildingEquipmentInd>
      <ReportInvestmentsOtherSecInd referenceDocumentId="IRS990ScheduleD">true</ReportInvestmentsOtherSecInd>
      <ReportProgramRelatedInvstInd referenceDocumentId="IRS990ScheduleD">false</ReportProgramRelatedInvstInd>
      <ReportOtherAssetsInd referenceDocumentId="IRS990ScheduleD">false</ReportOtherAssetsInd>
      <ReportOtherLiabilitiesInd referenceDocumentId="IRS990ScheduleD">true</ReportOtherLiabilitiesInd>
      <IncludeFIN48FootnoteInd referenceDocumentId="IRS990ScheduleD">true</IncludeFIN48FootnoteInd>
      <IndependentAuditFinclStmtInd referenceDocumentId="IRS990ScheduleD">false</IndependentAuditFinclStmtInd>
      <ConsolidatedAuditFinclStmtInd referenceDocumentId="IRS990ScheduleD">true</ConsolidatedAuditFinclStmtInd>
      <SchoolOperatingInd>false</SchoolOperatingInd>
      <ForeignOfficeInd>true</ForeignOfficeInd>
      <ForeignActivitiesInd referenceDocumentId="IRS990ScheduleF">true</ForeignActivitiesInd>
      <MoreThan5000KToOrgInd referenceDocumentId="IRS990ScheduleF">true</MoreThan5000KToOrgInd>
      <MoreThan5000KToIndividualsInd referenceDocumentId="IRS990ScheduleF">false</MoreThan5000KToIndividualsInd>
      <ProfessionalFundraisingInd referenceDocumentId="IRS990ScheduleG">true</ProfessionalFundraisingInd>
      <FundraisingActivitiesInd referenceDocumentId="IRS990ScheduleG">true</FundraisingActivitiesInd>
      <GamingActivitiesInd referenceDocumentId="IRS990ScheduleG">true</GamingActivitiesInd>
      <OperateHospitalInd>false</OperateHospitalInd>
      <GrantsToOrganizationsInd referenceDocumentId="IRS990ScheduleI">true</GrantsToOrganizationsInd>
      <GrantsToIndividualsInd referenceDocumentId="IRS990ScheduleI">false</GrantsToIndividualsInd>
      <ScheduleJRequiredInd referenceDocumentId="IRS990ScheduleJ">true</ScheduleJRequiredInd>
      <TaxExemptBondsInd>false</TaxExemptBondsInd>
      <EngagedInExcessBenefitTransInd referenceDocumentId="IRS990ScheduleL">false</EngagedInExcessBenefitTransInd>
      <PYExcessBenefitTransInd referenceDocumentId="IRS990ScheduleL">false</PYExcessBenefitTransInd>
      <LoanOutstandingInd referenceDocumentId="IRS990ScheduleL">false</LoanOutstandingInd>
      <GrantToRelatedPersonInd referenceDocumentId="IRS990ScheduleL">false</GrantToRelatedPersonInd>
      <BusinessRlnWithOrgMemInd referenceDocumentId="IRS990ScheduleL">false</BusinessRlnWithOrgMemInd>
      <BusinessRlnWithFamMemInd referenceDocumentId="IRS990ScheduleL">true</BusinessRlnWithFamMemInd>
      <BusinessRlnWithOfficerEntInd referenceDocumentId="IRS990ScheduleL">false</BusinessRlnWithOfficerEntInd>
      <DeductibleNonCashContriInd referenceDocumentId="IRS990ScheduleM">true</DeductibleNonCashContriInd>
      <DeductibleArtContributionInd referenceDocumentId="IRS990ScheduleM">false</DeductibleArtContributionInd>
      <TerminateOperationsInd>false</TerminateOperationsInd>
      <PartialLiquidationInd>false</PartialLiquidationInd>
      <DisregardedEntityInd referenceDocumentId="IRS990ScheduleR">true</DisregardedEntityInd>
      <RelatedEntityInd referenceDocumentId="IRS990ScheduleR">true</RelatedEntityInd>
      <RelatedOrganizationCtrlEntInd>true</RelatedOrganizationCtrlEntInd>
      <TransactionWithControlEntInd referenceDocumentId="IRS990ScheduleR">false</TransactionWithControlEntInd>
      <TrnsfrExmptNonChrtblRltdOrgInd referenceDocumentId="IRS990ScheduleR">false</TrnsfrExmptNonChrtblRltdOrgInd>
      <ActivitiesConductedPrtshpInd referenceDocumentId="IRS990ScheduleR">false</ActivitiesConductedPrtshpInd>
      <ScheduleORequiredInd>true</ScheduleORequiredInd>
      <InfoInScheduleOPartVInd>X</InfoInScheduleOPartVInd>
      <IRPDocumentCnt>964</IRPDocumentCnt>
      <IRPDocumentW2GCnt>6</IRPDocumentW2GCnt>
      <BackupWthldComplianceInd>true</BackupWthldComplianceInd>
      <EmployeeCnt>886</EmployeeCnt>
      <EmploymentTaxReturnsFiledInd>true</EmploymentTaxReturnsFiledInd>
      <UnrelatedBusIncmOverLimitInd>true</UnrelatedBusIncmOverLimitInd>
      <Form990TFiledInd>true</Form990TFiledInd>
      <ForeignFinancialAccountInd>true</ForeignFinancialAccountInd>
      <ForeignCountryCd>IS</ForeignCountryCd>
      <ForeignCountryCd>DA</ForeignCountryCd>
      <ForeignCountryCd>NL</ForeignCountryCd>
      <ProhibitedTaxShelterTransInd>false</ProhibitedTaxShelterTransInd>
      <TaxablePartyNotificationInd>false</TaxablePartyNotificationInd>
      <NondeductibleContributionsInd>false</NondeductibleContributionsInd>
      <QuidProQuoContributionsInd>true</QuidProQuoContributionsInd>
      <QuidProQuoContriDisclInd>true</QuidProQuoContriDisclInd>
      <Form8282PropertyDisposedOfInd>false</Form8282PropertyDisposedOfInd>
      <RcvFndsToPayPrsnlBnftCntrctInd>false</RcvFndsToPayPrsnlBnftCntrctInd>
      <PayPremiumsPrsnlBnftCntrctInd>false</PayPremiumsPrsnlBnftCntrctInd>
      <Form1098CFiledInd>true</Form1098CFiledInd>
      <IndoorTanningServicesInd>false</IndoorTanningServicesInd>
      <InfoInScheduleOPartVIInd>X</InfoInScheduleOPartVIInd>
      <GoverningBodyVotingMembersCnt>33</GoverningBodyVotingMembersCnt>
      <IndependentVotingMemberCnt>31</IndependentVotingMemberCnt>
      <FamilyOrBusinessRlnInd>false</FamilyOrBusinessRlnInd>
      <DelegationOfMgmtDutiesInd>false</DelegationOfMgmtDutiesInd>
      <ChangeToOrgDocumentsInd>false</ChangeToOrgDocumentsInd>
      <MaterialDiversionOrMisuseInd>false</MaterialDiversionOrMisuseInd>
      <MembersOrStockholdersInd>false</MembersOrStockholdersInd>
      <ElectionOfBoardMembersInd>false</ElectionOfBoardMembersInd>
      <DecisionsSubjectToApprovaInd>false</DecisionsSubjectToApprovaInd>
      <MinutesOfGoverningBodyInd>true</MinutesOfGoverningBodyInd>
      <MinutesOfCommitteesInd>true</MinutesOfCommitteesInd>
      <OfficerMailingAddressInd>false</OfficerMailingAddressInd>
      <LocalChaptersInd>true</LocalChaptersInd>
      <PoliciesReferenceChaptersInd>true</PoliciesReferenceChaptersInd>
      <Form990ProvidedToGvrnBodyInd>true</Form990ProvidedToGvrnBodyInd>
      <ConflictOfInterestPolicyInd>true</ConflictOfInterestPolicyInd>
      <AnnualDisclosureCoveredPrsnInd>true</AnnualDisclosureCoveredPrsnInd>
      <RegularMonitoringEnfrcInd>true</RegularMonitoringEnfrcInd>
      <WhistleblowerPolicyInd>true</WhistleblowerPolicyInd>
      <DocumentRetentionPolicyInd>true</DocumentRetentionPolicyInd>
      <CompensationProcessCEOInd>true</CompensationProcessCEOInd>
      <CompensationProcessOtherInd>true</CompensationProcessOtherInd>
      <InvestmentInJointVentureInd>true</InvestmentInJointVentureInd>
      <WrittenPolicyOrProcedureInd>true</WrittenPolicyOrProcedureInd>
      <StatesWhereCopyOfReturnIsFldCd>AL</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>AK</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>AZ</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>AR</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>CA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>CO</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>CT</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>DE</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>DC</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>FL</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>GA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>HI</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>ID</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>IL</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>IN</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>IA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>KS</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>KY</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>LA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>ME</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MD</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MI</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MN</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MS</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MO</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MT</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NE</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NV</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NH</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NJ</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NM</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NY</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NC</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>ND</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>OH</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>OK</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>OR</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>PA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>RI</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>SC</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>SD</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>TN</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>TX</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>UT</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>VT</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>VA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>WA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>WV</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>WI</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>WY</StatesWhereCopyOfReturnIsFldCd>
      <OwnWebsiteInd>X</OwnWebsiteInd>
      <UponRequestInd>X</UponRequestInd>
      <BooksInCareOfDetail>
        <PersonNm>GARY CURTO CO JDRF INT</PersonNm>
        <PhoneNum>2124797551</PhoneNum>
        <USAddress>
          <AddressLine1Txt>26 BROADWAY 1TH FL</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10004</ZIPCd>
        </USAddress>
      </BooksInCareOfDetail>
      <Form990PartVIISectionAGrp>
        <PersonNm>MAARTEN DE GROOT FY15-17</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>LORNE SHIFF FY15-17</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>NICOLE JOHNSON FY16-17</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>MIKE LEE FY16-18</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>LARRY SOLER FY16-18</PersonNm>
        <TitleTxt>SECRETARY/CHAIR, NOM &amp; GOV</TitleTxt>
        <AverageHoursPerWeekRt>7.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>WENDY WOOD FY16-18</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>5.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>NANETTE DETURK FY17-19</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>MICHELLE GRIFFIN FY17-19</PersonNm>
        <TitleTxt>CHAIR, DEVELOPMENT</TitleTxt>
        <AverageHoursPerWeekRt>7.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>STEPHEN NEWMAN MD FY17-19</PersonNm>
        <TitleTxt>CHAIR, RESEARCH</TitleTxt>
        <AverageHoursPerWeekRt>7.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>LISA ALTMAN FY15-17</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>GRANT BEARD FY15-17</PersonNm>
        <TitleTxt>TREASURER/CHAIR, FINANCE</TitleTxt>
        <AverageHoursPerWeekRt>7.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>RANDY ANDERSON FY15-17</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>TIMOTHY CLARK FY15-17</PersonNm>
        <TitleTxt>CHAIR, INVESTMENT</TitleTxt>
        <AverageHoursPerWeekRt>7.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>MARK FISCHER-COLBRIE FY16-18</PersonNm>
        <TitleTxt>CHAIRMAN OF THE BOARD</TitleTxt>
        <AverageHoursPerWeekRt>20.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>SCOTT MCCORMICK FY15-17</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>LISA REED FY15-17</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>RED MAXWELL FY15-17</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>MARVIN DAITCH FY16-18</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>PAM EDMONDS FY16-18</PersonNm>
        <TitleTxt>CHAIR, ADVOCACY</TitleTxt>
        <AverageHoursPerWeekRt>7.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>PAT MCFEELEY FY16-17</PersonNm>
        <TitleTxt>CHAIR, CHANCELLORS</TitleTxt>
        <AverageHoursPerWeekRt>7.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>JEFF PLUMER FY16-18</PersonNm>
        <TitleTxt>CHAIR, AUDIT</TitleTxt>
        <AverageHoursPerWeekRt>7.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>LORRAINE STIEHL FY15-17</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>LISA WALLACK FY16-18</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>SEAN DOHERTY FY17-19</PersonNm>
        <TitleTxt>CHAIR, JDRF T1D FUND LLC</TitleTxt>
        <AverageHoursPerWeekRt>7.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>PAUL HEATH FY17-19</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>KAREN JORDAN FY17-19</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>JOHN KAMPFE FY17-19</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>ELLEN LEAKE FY17-19</PersonNm>
        <TitleTxt>BOARD VICE-CHAIR</TitleTxt>
        <AverageHoursPerWeekRt>10.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>DOUG LOWENSTEIN FY17-19</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>DAYTON OGDEN FY17-19</PersonNm>
        <TitleTxt>CHAIR, TALENT &amp; COMPENSATION</TitleTxt>
        <AverageHoursPerWeekRt>7.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>ANGIE PLATT FY17-19</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>JERRY WISLER FY17-19</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>KAREY L WITTY FY17-19</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>DEREK RAPP</PersonNm>
        <TitleTxt>PRESIDENT AND CEO</TitleTxt>
        <AverageHoursPerWeekRt>50.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>725000</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>48715</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>SANDRA HIJIKATA</PersonNm>
        <TitleTxt>CHIEF DEV OFFICER &amp; ASST. SECY</TitleTxt>
        <AverageHoursPerWeekRt>50.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>368333</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>18280</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>MARK GREENE</PersonNm>
        <TitleTxt>CFO &amp; ASST. TRES</TitleTxt>
        <AverageHoursPerWeekRt>50.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>363125</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>22288</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>JILL CLARK</PersonNm>
        <TitleTxt>CHIEF OF STAFF &amp; ASST. SECY</TitleTxt>
        <AverageHoursPerWeekRt>50.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>240831</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>14703</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>JONATHAN R BEHR</PersonNm>
        <TitleTxt>MANAGING DIRECTOR JDRF-T1D FND</TitleTxt>
        <AverageHoursPerWeekRt>50.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <KeyEmployeeInd>X</KeyEmployeeInd>
        <ReportableCompFromOrgAmt>25000</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>JULIA GREENSTEIN</PersonNm>
        <TitleTxt>VP RESEARCH</TitleTxt>
        <AverageHoursPerWeekRt>50.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>282800</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>14613</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>AARON KOWALSKI</PersonNm>
        <TitleTxt>CHIEF MISSION OFFICER</TitleTxt>
        <AverageHoursPerWeekRt>50.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>350000</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>35661</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>RICHARD INSEL ENDED 63016</PersonNm>
        <TitleTxt>CHIEF SCIENTIFIC OFFICER</TitleTxt>
        <AverageHoursPerWeekRt>50.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>605102</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>27345</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>MARGO LUCERO</PersonNm>
        <TitleTxt>SVP CORPORATE DEVELOPMENT</TitleTxt>
        <AverageHoursPerWeekRt>50.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>268000</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>38273</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>STEVEN GRIFFEN MD</PersonNm>
        <TitleTxt>SVP RESEARCH</TitleTxt>
        <AverageHoursPerWeekRt>50.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>377033</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>42547</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <TotalReportableCompFromOrgAmt>3605224</TotalReportableCompFromOrgAmt>
      <TotReportableCompRltdOrgAmt>0</TotReportableCompRltdOrgAmt>
      <TotalOtherCompensationAmt>262425</TotalOtherCompensationAmt>
      <IndivRcvdGreaterThan100KCnt>149</IndivRcvdGreaterThan100KCnt>
      <FormerOfcrEmployeesListedInd>false</FormerOfcrEmployeesListedInd>
      <TotalCompGreaterThan150KInd>true</TotalCompGreaterThan150KInd>
      <CompensationFromOtherSrcsInd>false</CompensationFromOtherSrcsInd>
      <ContractorCompensationGrp>
        <ContractorName>
          <PersonNm>SIX DEGREES MEDICAL CONSULTING</PersonNm>
        </ContractorName>
        <ContractorAddress>
          <ForeignAddress>
            <AddressLine1Txt>175 BLOOR ST</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <ProvinceOrStateNm>0</ProvinceOrStateNm>
            <CountryCd>CA</CountryCd>
          </ForeignAddress>
        </ContractorAddress>
        <ServicesDesc>FACULTY TRAINING</ServicesDesc>
        <CompensationAmt>578850</CompensationAmt>
      </ContractorCompensationGrp>
      <ContractorCompensationGrp>
        <ContractorName>
          <PersonNm>10UP LLC</PersonNm>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>2765 CARRADALE DR</AddressLine1Txt>
            <CityNm>ROSEVILLE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>95661</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>WEB DEVELOPMENT</ServicesDesc>
        <CompensationAmt>567981</CompensationAmt>
      </ContractorCompensationGrp>
      <ContractorCompensationGrp>
        <ContractorName>
          <PersonNm>CDS GLOBAL</PersonNm>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>1901 BELL AVE</AddressLine1Txt>
            <CityNm>DES MOINES</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>50315</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>3RD PARTY LOCK BOX</ServicesDesc>
        <CompensationAmt>542650</CompensationAmt>
      </ContractorCompensationGrp>
      <ContractorCompensationGrp>
        <ContractorName>
          <PersonNm>STRAIGHTLINE INTERNATIONAL</PersonNm>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>107 GRAND STREET 6</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10013</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>PROGRAMMING SERVICES</ServicesDesc>
        <CompensationAmt>457810</CompensationAmt>
      </ContractorCompensationGrp>
      <ContractorCompensationGrp>
        <ContractorName>
          <PersonNm>STOKES AUCTION GROUP</PersonNm>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>740 MUNEVAR DR</AddressLine1Txt>
            <CityNm>CARIDIFF BY THE SEA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92007</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>AUCTIONEER SERVICES</ServicesDesc>
        <CompensationAmt>350750</CompensationAmt>
      </ContractorCompensationGrp>
      <CntrctRcvdGreaterThan100KCnt>39</CntrctRcvdGreaterThan100KCnt>
      <FederatedCampaignsAmt>4488030</FederatedCampaignsAmt>
      <FundraisingAmt>127671682</FundraisingAmt>
      <AllOtherContributionsAmt>67737140</AllOtherContributionsAmt>
      <NoncashContributionsAmt>17224248</NoncashContributionsAmt>
      <TotalContributionsAmt>199896852</TotalContributionsAmt>
      <TotalProgramServiceRevenueAmt>0</TotalProgramServiceRevenueAmt>
      <InvestmentIncomeGrp>
        <TotalRevenueColumnAmt>593975</TotalRevenueColumnAmt>
        <UnrelatedBusinessRevenueAmt>45150</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>548825</ExclusionAmt>
      </InvestmentIncomeGrp>
      <IncmFromInvestBondProceedsGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
      </IncmFromInvestBondProceedsGrp>
      <RoyaltiesRevenueGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
      </RoyaltiesRevenueGrp>
      <RentalIncomeOrLossGrp>
        <RealAmt>0</RealAmt>
        <PersonalAmt>0</PersonalAmt>
      </RentalIncomeOrLossGrp>
      <NetRentalIncomeOrLossGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
      </NetRentalIncomeOrLossGrp>
      <GrossAmountSalesAssetsGrp>
        <SecuritiesAmt>1017000</SecuritiesAmt>
      </GrossAmountSalesAssetsGrp>
      <LessCostOthBasisSalesExpnssGrp>
        <SecuritiesAmt>383706</SecuritiesAmt>
      </LessCostOthBasisSalesExpnssGrp>
      <GainOrLossGrp>
        <SecuritiesAmt>633294</SecuritiesAmt>
      </GainOrLossGrp>
      <NetGainOrLossInvestmentsGrp>
        <TotalRevenueColumnAmt>633294</TotalRevenueColumnAmt>
        <ExclusionAmt>633294</ExclusionAmt>
      </NetGainOrLossInvestmentsGrp>
      <FundraisingGrossIncomeAmt>27152973</FundraisingGrossIncomeAmt>
      <ContriRptFundraisingEventAmt>127671682</ContriRptFundraisingEventAmt>
      <FundraisingDirectExpensesAmt>27152973</FundraisingDirectExpensesAmt>
      <GamingGrossIncomeAmt>1106452</GamingGrossIncomeAmt>
      <GamingDirectExpensesAmt>259790</GamingDirectExpensesAmt>
      <NetIncomeFromGamingGrp>
        <TotalRevenueColumnAmt>846662</TotalRevenueColumnAmt>
        <ExclusionAmt>846662</ExclusionAmt>
      </NetIncomeFromGamingGrp>
      <GrossSalesOfInventoryAmt>0</GrossSalesOfInventoryAmt>
      <CostOfGoodsSoldAmt>0</CostOfGoodsSoldAmt>
      <NetIncomeOrLossGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
      </NetIncomeOrLossGrp>
      <OtherRevenueMiscGrp>
        <Desc>MISCELLANEOUS PROGRAM REVENUE</Desc>
        <BusinessCd>900099</BusinessCd>
        <TotalRevenueColumnAmt>283014</TotalRevenueColumnAmt>
        <ExclusionAmt>283014</ExclusionAmt>
      </OtherRevenueMiscGrp>
      <OtherRevenueTotalAmt>283014</OtherRevenueTotalAmt>
      <TotalRevenueGrp>
        <TotalRevenueColumnAmt>202253797</TotalRevenueColumnAmt>
        <UnrelatedBusinessRevenueAmt>45150</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>2311795</ExclusionAmt>
      </TotalRevenueGrp>
      <GrantsToDomesticOrgsGrp>
        <TotalAmt>56018820</TotalAmt>
        <ProgramServicesAmt>56018820</ProgramServicesAmt>
      </GrantsToDomesticOrgsGrp>
      <GrantsToDomesticIndividualsGrp>
        <TotalAmt>0</TotalAmt>
      </GrantsToDomesticIndividualsGrp>
      <ForeignGrantsGrp>
        <TotalAmt>22990836</TotalAmt>
        <ProgramServicesAmt>22990836</ProgramServicesAmt>
      </ForeignGrantsGrp>
      <BenefitsToMembersGrp>
        <TotalAmt>0</TotalAmt>
      </BenefitsToMembersGrp>
      <CompCurrentOfcrDirectorsGrp>
        <TotalAmt>1784272</TotalAmt>
        <ProgramServicesAmt>1138366</ProgramServicesAmt>
        <ManagementAndGeneralAmt>231955</ManagementAndGeneralAmt>
        <FundraisingAmt>413951</FundraisingAmt>
      </CompCurrentOfcrDirectorsGrp>
      <CompDisqualPersonsGrp>
        <TotalAmt>108774</TotalAmt>
        <ProgramServicesAmt>74292</ProgramServicesAmt>
        <ManagementAndGeneralAmt>14141</ManagementAndGeneralAmt>
        <FundraisingAmt>20341</FundraisingAmt>
      </CompDisqualPersonsGrp>
      <OtherSalariesAndWagesGrp>
        <TotalAmt>58996885</TotalAmt>
        <ProgramServicesAmt>37635118</ProgramServicesAmt>
        <ManagementAndGeneralAmt>7669595</ManagementAndGeneralAmt>
        <FundraisingAmt>13692172</FundraisingAmt>
      </OtherSalariesAndWagesGrp>
      <PensionPlanContributionsGrp>
        <TotalAmt>1467676</TotalAmt>
        <ProgramServicesAmt>936377</ProgramServicesAmt>
        <ManagementAndGeneralAmt>190798</ManagementAndGeneralAmt>
        <FundraisingAmt>340501</FundraisingAmt>
      </PensionPlanContributionsGrp>
      <OtherEmployeeBenefitsGrp>
        <TotalAmt>8952280</TotalAmt>
        <ProgramServicesAmt>5711555</ProgramServicesAmt>
        <ManagementAndGeneralAmt>1163796</ManagementAndGeneralAmt>
        <FundraisingAmt>2076929</FundraisingAmt>
      </OtherEmployeeBenefitsGrp>
      <PayrollTaxesGrp>
        <TotalAmt>4037397</TotalAmt>
        <ProgramServicesAmt>2794875</ProgramServicesAmt>
        <ManagementAndGeneralAmt>646918</ManagementAndGeneralAmt>
        <FundraisingAmt>595604</FundraisingAmt>
      </PayrollTaxesGrp>
      <FeesForServicesManagementGrp>
        <TotalAmt>1475007</TotalAmt>
        <ProgramServicesAmt>1035136</ProgramServicesAmt>
        <ManagementAndGeneralAmt>134882</ManagementAndGeneralAmt>
        <FundraisingAmt>304989</FundraisingAmt>
      </FeesForServicesManagementGrp>
      <FeesForServicesLegalGrp>
        <TotalAmt>673601</TotalAmt>
        <ProgramServicesAmt>569193</ProgramServicesAmt>
        <ManagementAndGeneralAmt>33680</ManagementAndGeneralAmt>
        <FundraisingAmt>70728</FundraisingAmt>
      </FeesForServicesLegalGrp>
      <FeesForServicesAccountingGrp>
        <TotalAmt>233403</TotalAmt>
        <ProgramServicesAmt>197226</ProgramServicesAmt>
        <ManagementAndGeneralAmt>11670</ManagementAndGeneralAmt>
        <FundraisingAmt>24507</FundraisingAmt>
      </FeesForServicesAccountingGrp>
      <FeesForServicesLobbyingGrp>
        <TotalAmt>623411</TotalAmt>
        <ProgramServicesAmt>623411</ProgramServicesAmt>
      </FeesForServicesLobbyingGrp>
      <FeesForServicesProfFundraising>
        <TotalAmt>0</TotalAmt>
      </FeesForServicesProfFundraising>
      <FeesForSrvcInvstMgmntFeesGrp>
        <TotalAmt>452370</TotalAmt>
        <ManagementAndGeneralAmt>452370</ManagementAndGeneralAmt>
      </FeesForSrvcInvstMgmntFeesGrp>
      <FeesForServicesOtherGrp>
        <TotalAmt>3166685</TotalAmt>
        <ProgramServicesAmt>2675849</ProgramServicesAmt>
        <ManagementAndGeneralAmt>158334</ManagementAndGeneralAmt>
        <FundraisingAmt>332502</FundraisingAmt>
      </FeesForServicesOtherGrp>
      <AdvertisingGrp>
        <TotalAmt>5167896</TotalAmt>
        <ProgramServicesAmt>2756198</ProgramServicesAmt>
        <ManagementAndGeneralAmt>432525</ManagementAndGeneralAmt>
        <FundraisingAmt>1979173</FundraisingAmt>
      </AdvertisingGrp>
      <OfficeExpensesGrp>
        <TotalAmt>1188854</TotalAmt>
        <ProgramServicesAmt>722823</ProgramServicesAmt>
        <ManagementAndGeneralAmt>205672</ManagementAndGeneralAmt>
        <FundraisingAmt>260359</FundraisingAmt>
      </OfficeExpensesGrp>
      <InformationTechnologyGrp>
        <TotalAmt>3941474</TotalAmt>
        <ProgramServicesAmt>2396416</ProgramServicesAmt>
        <ManagementAndGeneralAmt>681875</ManagementAndGeneralAmt>
        <FundraisingAmt>863183</FundraisingAmt>
      </InformationTechnologyGrp>
      <RoyaltiesGrp>
        <TotalAmt>0</TotalAmt>
      </RoyaltiesGrp>
      <OccupancyGrp>
        <TotalAmt>8313000</TotalAmt>
        <ProgramServicesAmt>5026204</ProgramServicesAmt>
        <ManagementAndGeneralAmt>1439436</ManagementAndGeneralAmt>
        <FundraisingAmt>1847360</FundraisingAmt>
      </OccupancyGrp>
      <TravelGrp>
        <TotalAmt>2413804</TotalAmt>
        <ProgramServicesAmt>1734318</ProgramServicesAmt>
        <ManagementAndGeneralAmt>229794</ManagementAndGeneralAmt>
        <FundraisingAmt>449692</FundraisingAmt>
      </TravelGrp>
      <PymtTravelEntrtnmntPubOfclGrp>
        <TotalAmt>0</TotalAmt>
      </PymtTravelEntrtnmntPubOfclGrp>
      <ConferencesMeetingsGrp>
        <TotalAmt>2696865</TotalAmt>
        <ProgramServicesAmt>1966015</ProgramServicesAmt>
        <ManagementAndGeneralAmt>256202</ManagementAndGeneralAmt>
        <FundraisingAmt>474648</FundraisingAmt>
      </ConferencesMeetingsGrp>
      <InterestGrp>
        <TotalAmt>0</TotalAmt>
      </InterestGrp>
      <PaymentsToAffiliatesGrp>
        <TotalAmt>0</TotalAmt>
      </PaymentsToAffiliatesGrp>
      <DepreciationDepletionGrp>
        <TotalAmt>4629902</TotalAmt>
        <ProgramServicesAmt>2814980</ProgramServicesAmt>
        <ManagementAndGeneralAmt>800973</ManagementAndGeneralAmt>
        <FundraisingAmt>1013949</FundraisingAmt>
      </DepreciationDepletionGrp>
      <InsuranceGrp>
        <TotalAmt>524072</TotalAmt>
        <ProgramServicesAmt>318636</ProgramServicesAmt>
        <ManagementAndGeneralAmt>90664</ManagementAndGeneralAmt>
        <FundraisingAmt>114772</FundraisingAmt>
      </InsuranceGrp>
      <OtherExpensesGrp>
        <Desc>OUTREACH EXPENSES</Desc>
        <TotalAmt>2021589</TotalAmt>
        <ProgramServicesAmt>1286944</ProgramServicesAmt>
        <ManagementAndGeneralAmt>277766</ManagementAndGeneralAmt>
        <FundraisingAmt>456879</FundraisingAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>DUES &amp; FEES</Desc>
        <TotalAmt>1492960</TotalAmt>
        <ProgramServicesAmt>950418</ProgramServicesAmt>
        <ManagementAndGeneralAmt>205133</ManagementAndGeneralAmt>
        <FundraisingAmt>337409</FundraisingAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>OTHER MISC EXPENSES</Desc>
        <TotalAmt>417499</TotalAmt>
        <ProgramServicesAmt>265780</ProgramServicesAmt>
        <ManagementAndGeneralAmt>57364</ManagementAndGeneralAmt>
        <FundraisingAmt>94355</FundraisingAmt>
      </OtherExpensesGrp>
      <TotalFunctionalExpensesGrp>
        <TotalAmt>193789332</TotalAmt>
        <ProgramServicesAmt>152639786</ProgramServicesAmt>
        <ManagementAndGeneralAmt>15385543</ManagementAndGeneralAmt>
        <FundraisingAmt>25764003</FundraisingAmt>
      </TotalFunctionalExpensesGrp>
      <JointCostsInd>X</JointCostsInd>
      <TotalJointCostsGrp>
        <TotalAmt>2105461</TotalAmt>
        <ProgramServicesAmt>743506</ProgramServicesAmt>
        <ManagementAndGeneralAmt>111868</ManagementAndGeneralAmt>
        <FundraisingAmt>1250087</FundraisingAmt>
      </TotalJointCostsGrp>
      <CashNonInterestBearingGrp>
        <BOYAmt>30314175</BOYAmt>
        <EOYAmt>23695495</EOYAmt>
      </CashNonInterestBearingGrp>
      <SavingsAndTempCashInvstGrp>
        <BOYAmt>34391736</BOYAmt>
        <EOYAmt>30545972</EOYAmt>
      </SavingsAndTempCashInvstGrp>
      <PledgesAndGrantsReceivableGrp>
        <BOYAmt>25415000</BOYAmt>
        <EOYAmt>28143186</EOYAmt>
      </PledgesAndGrantsReceivableGrp>
      <AccountsReceivableGrp>
        <BOYAmt>15598016</BOYAmt>
        <EOYAmt>14274402</EOYAmt>
      </AccountsReceivableGrp>
      <ReceivablesFromOfficersEtcGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </ReceivablesFromOfficersEtcGrp>
      <RcvblFromDisqualifiedPrsnGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </RcvblFromDisqualifiedPrsnGrp>
      <OthNotesLoansReceivableNetGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>5000000</EOYAmt>
      </OthNotesLoansReceivableNetGrp>
      <InventoriesForSaleOrUseGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </InventoriesForSaleOrUseGrp>
      <PrepaidExpensesDefrdChargesGrp>
        <BOYAmt>4604817</BOYAmt>
        <EOYAmt>5592386</EOYAmt>
      </PrepaidExpensesDefrdChargesGrp>
      <LandBldgEquipCostOrOtherBssAmt>31236775</LandBldgEquipCostOrOtherBssAmt>
      <LandBldgEquipAccumDeprecAmt>21516895</LandBldgEquipAccumDeprecAmt>
      <LandBldgEquipBasisNetGrp>
        <BOYAmt>13589735</BOYAmt>
        <EOYAmt>9719880</EOYAmt>
      </LandBldgEquipBasisNetGrp>
      <InvestmentsPubTradedSecGrp>
        <BOYAmt>34442190</BOYAmt>
        <EOYAmt>38164626</EOYAmt>
      </InvestmentsPubTradedSecGrp>
      <InvestmentsOtherSecuritiesGrp>
        <BOYAmt>36283061</BOYAmt>
        <EOYAmt>39867626</EOYAmt>
      </InvestmentsOtherSecuritiesGrp>
      <InvestmentsProgramRelatedGrp>
        <BOYAmt>2454398</BOYAmt>
        <EOYAmt>3750000</EOYAmt>
      </InvestmentsProgramRelatedGrp>
      <IntangibleAssetsGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </IntangibleAssetsGrp>
      <OtherAssetsTotalGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </OtherAssetsTotalGrp>
      <TotalAssetsGrp>
        <BOYAmt>197093128</BOYAmt>
        <EOYAmt>198753573</EOYAmt>
      </TotalAssetsGrp>
      <AccountsPayableAccrExpnssGrp>
        <BOYAmt>16335885</BOYAmt>
        <EOYAmt>16729137</EOYAmt>
      </AccountsPayableAccrExpnssGrp>
      <GrantsPayableGrp>
        <BOYAmt>105778368</BOYAmt>
        <EOYAmt>94060180</EOYAmt>
      </GrantsPayableGrp>
      <DeferredRevenueGrp>
        <BOYAmt>8340978</BOYAmt>
        <EOYAmt>7934693</EOYAmt>
      </DeferredRevenueGrp>
      <TaxExemptBondLiabilitiesGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </TaxExemptBondLiabilitiesGrp>
      <EscrowAccountLiabilityGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </EscrowAccountLiabilityGrp>
      <LoansFromOfficersDirectorsGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </LoansFromOfficersDirectorsGrp>
      <MortgNotesPyblScrdInvstPropGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </MortgNotesPyblScrdInvstPropGrp>
      <UnsecuredNotesLoansPayableGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </UnsecuredNotesLoansPayableGrp>
      <OtherLiabilitiesGrp>
        <BOYAmt>2742623</BOYAmt>
        <EOYAmt>2661059</EOYAmt>
      </OtherLiabilitiesGrp>
      <TotalLiabilitiesGrp>
        <BOYAmt>133197854</BOYAmt>
        <EOYAmt>121385069</EOYAmt>
      </TotalLiabilitiesGrp>
      <OrganizationFollowsSFAS117Ind>X</OrganizationFollowsSFAS117Ind>
      <UnrestrictedNetAssetsGrp>
        <BOYAmt>24131379</BOYAmt>
        <EOYAmt>39586000</EOYAmt>
      </UnrestrictedNetAssetsGrp>
      <TemporarilyRstrNetAssetsGrp>
        <BOYAmt>32690094</BOYAmt>
        <EOYAmt>30441504</EOYAmt>
      </TemporarilyRstrNetAssetsGrp>
      <PermanentlyRstrNetAssetsGrp>
        <BOYAmt>7073801</BOYAmt>
        <EOYAmt>7341000</EOYAmt>
      </PermanentlyRstrNetAssetsGrp>
      <TotalNetAssetsFundBalanceGrp>
        <BOYAmt>63895274</BOYAmt>
        <EOYAmt>77368504</EOYAmt>
      </TotalNetAssetsFundBalanceGrp>
      <TotLiabNetAssetsFundBalanceGrp>
        <BOYAmt>197093128</BOYAmt>
        <EOYAmt>198753573</EOYAmt>
      </TotLiabNetAssetsFundBalanceGrp>
      <ReconcilationRevenueExpnssAmt>8464465</ReconcilationRevenueExpnssAmt>
      <NetUnrlzdGainsLossesInvstAmt>5008765</NetUnrlzdGainsLossesInvstAmt>
      <MethodOfAccountingAccrualInd>X</MethodOfAccountingAccrualInd>
      <AccountantCompileOrReviewInd>false</AccountantCompileOrReviewInd>
      <FSAuditedInd>true</FSAuditedInd>
      <FSAuditedBasisGrp>
        <ConsolidatedBasisFinclStmtInd>X</ConsolidatedBasisFinclStmtInd>
      </FSAuditedBasisGrp>
      <AuditCommitteeInd>true</AuditCommitteeInd>
      <FederalGrantAuditRequiredInd>false</FederalGrantAuditRequiredInd>
    </IRS990>
    <IRS990ScheduleA documentId="IRS990ScheduleA">
      <PublicOrganization170Ind>X</PublicOrganization170Ind>
      <GiftsGrantsContriRcvd170Grp>
        <CurrentTaxYearMinus4YearsAmt>196010663</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>210068935</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>198918214</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>196804267</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>199896852</CurrentTaxYearAmt>
        <TotalAmt>1001698931</TotalAmt>
      </GiftsGrantsContriRcvd170Grp>
      <TaxRevLeviedOrgnztnlBnft170Grp>
        <TotalAmt>0</TotalAmt>
      </TaxRevLeviedOrgnztnlBnft170Grp>
      <GovtFurnSrvcFcltsVl170Grp>
        <TotalAmt>0</TotalAmt>
      </GovtFurnSrvcFcltsVl170Grp>
      <TotalCalendarYear170Grp>
        <CurrentTaxYearMinus4YearsAmt>196010663</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>210068935</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>198918214</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>196804267</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>199896852</CurrentTaxYearAmt>
        <TotalAmt>1001698931</TotalAmt>
      </TotalCalendarYear170Grp>
      <SubstantialContributorsTotAmt>5476665</SubstantialContributorsTotAmt>
      <PublicSupportTotal170Amt>996222266</PublicSupportTotal170Amt>
      <GrossInvestmentIncome170Grp>
        <CurrentTaxYearMinus4YearsAmt>2015080</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>1646615</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>987577</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>465379</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>548825</CurrentTaxYearAmt>
        <TotalAmt>5663476</TotalAmt>
      </GrossInvestmentIncome170Grp>
      <UnrelatedBusinessNetIncm170Grp>
        <CurrentTaxYearMinus4YearsAmt>29449</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>6810</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>2516</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>112437</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>33150</CurrentTaxYearAmt>
        <TotalAmt>184362</TotalAmt>
      </UnrelatedBusinessNetIncm170Grp>
      <OtherIncome170Grp>
        <CurrentTaxYearMinus4YearsAmt>74636</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>136667</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>256146</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>94769</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>283014</CurrentTaxYearAmt>
        <TotalAmt>845232</TotalAmt>
      </OtherIncome170Grp>
      <TotalSupportAmt>1008392001</TotalSupportAmt>
      <PublicSupportCY170Pct>0.98793</PublicSupportCY170Pct>
      <PublicSupportPY170Pct>0.98424</PublicSupportPY170Pct>
      <ThirtyThrPctSuprtTestsCY170Ind>X</ThirtyThrPctSuprtTestsCY170Ind>
    </IRS990ScheduleA>
    <IRS990ScheduleC documentId="IRS990ScheduleC">
      <TotalGrassrootsLobbyingGrp />
      <TotalDirectLobbyingGrp />
      <TotalLobbyingExpendGrp />
      <OtherExemptPurposeExpendGrp />
      <TotalExemptPurposeExpendGrp />
      <LobbyingNontaxableAmountGrp />
      <GrassrootsNontaxableGrp />
      <TotLbbyngGrassrootMnsNonTxGrp />
      <TotLbbyExpendMnsLbbyngNonTxGrp />
      <Form4720FiledInd>false</Form4720FiledInd>
      <VolunteersInd>true</VolunteersInd>
      <PaidStaffOrManagementInd>true</PaidStaffOrManagementInd>
      <MediaAdvertisementsInd>false</MediaAdvertisementsInd>
      <MailingsMembersInd>true</MailingsMembersInd>
      <MailingsMembersAmt>73969</MailingsMembersAmt>
      <PublicationsOrBroadcastInd>false</PublicationsOrBroadcastInd>
      <GrantsOtherOrganizationsInd>true</GrantsOtherOrganizationsInd>
      <GrantsOtherOrganizationsAmt>210</GrantsOtherOrganizationsAmt>
      <DirectContactLegislatorsInd>true</DirectContactLegislatorsInd>
      <DirectContactLegislatorsAmt>509616</DirectContactLegislatorsAmt>
      <RalliesDemonstrationsInd>true</RalliesDemonstrationsInd>
      <RalliesDemonstrationsAmt>202384</RalliesDemonstrationsAmt>
      <OtherActivitiesInd>false</OtherActivitiesInd>
      <TotalLobbyingExpendituresAmt>786179</TotalLobbyingExpendituresAmt>
      <NotDescribedSection501c3Ind>false</NotDescribedSection501c3Ind>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>JDRF LOBBYING ACTIVITIES</FormAndLineReferenceDesc>
        <ExplanationTxt>FORM 990- SCH-C- GENERAL STATEMENT OF ACTIVITIES JDRF is the leading global organization funding type 1 diabetes (T1D) research. Its strength lies in its exclusive focus and singular influence on the worldwide effort to end T1D. Through research and advocacy, JDRF is accelerating progress on the most promising opportunities to cure, prevent and treat T1D and its complications. JDRF's advocacy includes lobbying activity to ensure Congress continues to invest in critically important medical research and puts in place policies to advance the discovery, development, and delivery of better therapies for T1D. JDRF has been instrumental in securing the renewal of the Special Diabetes Program, which provides $150MM annually for T1D research at the National Institutes of Health. JDRF staff and volunteers communicate with government officials through email, phone calls, and meetings, to educate them on issues and encourage the advancement of legislation.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleC>
    <IRS990ScheduleD documentId="IRS990ScheduleD">
      <ArtPublicExhibitionAmountsGrp />
      <HeldWorksArtGrp />
      <CYEndwmtFundGrp>
        <BeginningYearBalanceAmt>7176427</BeginningYearBalanceAmt>
        <InvestmentEarningsOrLossesAmt>367446</InvestmentEarningsOrLossesAmt>
        <OtherExpendituresAmt>102000</OtherExpendituresAmt>
        <EndYearBalanceAmt>7441873</EndYearBalanceAmt>
      </CYEndwmtFundGrp>
      <CYMinus1YrEndwmtFundGrp>
        <BeginningYearBalanceAmt>7141514</BeginningYearBalanceAmt>
        <InvestmentEarningsOrLossesAmt>37913</InvestmentEarningsOrLossesAmt>
        <OtherExpendituresAmt>3000</OtherExpendituresAmt>
        <EndYearBalanceAmt>7176427</EndYearBalanceAmt>
      </CYMinus1YrEndwmtFundGrp>
      <CYMinus2YrEndwmtFundGrp>
        <BeginningYearBalanceAmt>7426222</BeginningYearBalanceAmt>
        <InvestmentEarningsOrLossesAmt>11292</InvestmentEarningsOrLossesAmt>
        <OtherExpendituresAmt>296000</OtherExpendituresAmt>
        <EndYearBalanceAmt>7141514</EndYearBalanceAmt>
      </CYMinus2YrEndwmtFundGrp>
      <CYMinus3YrEndwmtFundGrp>
        <BeginningYearBalanceAmt>6837461</BeginningYearBalanceAmt>
        <InvestmentEarningsOrLossesAmt>625761</InvestmentEarningsOrLossesAmt>
        <OtherExpendituresAmt>37000</OtherExpendituresAmt>
        <EndYearBalanceAmt>7426222</EndYearBalanceAmt>
      </CYMinus3YrEndwmtFundGrp>
      <CYMinus4YrEndwmtFundGrp>
        <BeginningYearBalanceAmt>6728240</BeginningYearBalanceAmt>
        <ContributionsAmt>100000</ContributionsAmt>
        <InvestmentEarningsOrLossesAmt>9221</InvestmentEarningsOrLossesAmt>
        <EndYearBalanceAmt>6837461</EndYearBalanceAmt>
      </CYMinus4YrEndwmtFundGrp>
      <PrmnntEndowmentBalanceEOYPct>0.98640</PrmnntEndowmentBalanceEOYPct>
      <TermEndowmentBalanceEOYPct>0.01360</TermEndowmentBalanceEOYPct>
      <EndowmentsHeldUnrelatedOrgInd>false</EndowmentsHeldUnrelatedOrgInd>
      <EndowmentsHeldRelatedOrgInd>false</EndowmentsHeldRelatedOrgInd>
      <LandGrp />
      <BuildingsGrp />
      <LeaseholdImprovementsGrp>
        <OtherCostOrOtherBasisAmt>4722775</OtherCostOrOtherBasisAmt>
        <DepreciationAmt>3278539</DepreciationAmt>
        <BookValueAmt>1444236</BookValueAmt>
      </LeaseholdImprovementsGrp>
      <EquipmentGrp>
        <OtherCostOrOtherBasisAmt>26514000</OtherCostOrOtherBasisAmt>
        <DepreciationAmt>18238356</DepreciationAmt>
        <BookValueAmt>8275644</BookValueAmt>
      </EquipmentGrp>
      <OtherLandBuildingsGrp />
      <TotalBookValueLandBuildingsAmt>9719880</TotalBookValueLandBuildingsAmt>
      <FinancialDerivativesGrp />
      <CloselyHeldEquityInterestsGrp />
      <OtherSecuritiesGrp>
        <Desc>HEDGE FUNDS</Desc>
        <BookValueAmt>22477058</BookValueAmt>
        <MethodValuationCd>F</MethodValuationCd>
      </OtherSecuritiesGrp>
      <OtherSecuritiesGrp>
        <Desc>US-NON-PUBLIC INVESTMENT FUNDS</Desc>
        <BookValueAmt>17390568</BookValueAmt>
        <MethodValuationCd>F</MethodValuationCd>
      </OtherSecuritiesGrp>
      <TotalBookValueSecuritiesAmt>39867626</TotalBookValueSecuritiesAmt>
      <FederalIncomeTaxLiabilityAmt>0</FederalIncomeTaxLiabilityAmt>
      <OtherLiabilitiesOrgGrp>
        <Desc>SPLIT INTEREST CHRT RMDR TRUST</Desc>
        <Amt>2661059</Amt>
      </OtherLiabilitiesOrgGrp>
      <TotalLiabilityAmt>2661059</TotalLiabilityAmt>
      <FootnoteTextInd>X</FootnoteTextInd>
      <TotalRevEtcAuditedFinclStmtAmt>206810192</TotalRevEtcAuditedFinclStmtAmt>
      <NetUnrealizedGainsInvstAmt>5008765</NetUnrealizedGainsInvstAmt>
      <RevenueNotReportedAmt>5008765</RevenueNotReportedAmt>
      <RevenueSubtotalAmt>201801427</RevenueSubtotalAmt>
      <InvestmentExpensesNotIncldAmt>452370</InvestmentExpensesNotIncldAmt>
      <RevenueNotReportedFinclStmtAmt>452370</RevenueNotReportedFinclStmtAmt>
      <TotalRevenuePerForm990Amt>202253797</TotalRevenuePerForm990Amt>
      <TotExpnsEtcAuditedFinclStmtAmt>193336962</TotExpnsEtcAuditedFinclStmtAmt>
      <ExpensesSubtotalAmt>193336962</ExpensesSubtotalAmt>
      <InvestmentExpensesNotIncld2Amt>452370</InvestmentExpensesNotIncld2Amt>
      <ExpensesNotRptFinclStmtAmt>452370</ExpensesNotRptFinclStmtAmt>
      <TotalExpensesPerForm990Amt>193789332</TotalExpensesPerForm990Amt>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>ORGANIZATION'S ENDOWMENT FUNDS</FormAndLineReferenceDesc>
        <ExplanationTxt>FORM 990, PART X, LINE 28 &amp; 29 &amp; SCH D, PART V THE ORGANIZATION UTILIZES EARNINGS ON ENDOWMENT FUNDS IN THE MANNER SPECIFIED BY THE DONOR AND/OR FOR SUPPORTING THE ORGANIZATIONS GENERAL EXEMPT PURPOSE.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>INCOME TAX POSITION OF JDRF INT.</FormAndLineReferenceDesc>
        <ExplanationTxt>990 SCH-D, PART X, LINE 2 JDRF IS A NOT FOR PROFIT ORGANIZATION EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501 (C) (3) OF THE INTERNAL REVENUE CODE AND IS ORGANIZED UNDER THE LAWS OF THE COMMONWEALTH OF PENNSYLVANIA. INCOME GENERATED FROM ACTIVITIES UNRELATED TO JDRFS EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. INCOME TAX LIABILITIES ARE RECOGNIZED WHEN SUCH POSITIONS ARE QUANTIFIABLE AND LIKELY TO BE REALIZED. UNRELATED BUSINESS INCOME TAX LIABILITY WAS INSIGNIFICANT FOR THE YEARS ENDING JUNE 30, 2017 AND 2016.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleD>
    <IRS990ScheduleF documentId="IRS990ScheduleF">
      <GrantRecordsMaintainedInd>true</GrantRecordsMaintainedInd>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>North America</RegionTxt>
        <TypeOfActivitiesConductedTxt>Grantmaking</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>RESEARCH GRANTS</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>4305000</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>Central America and the Caribbean</RegionTxt>
        <TypeOfActivitiesConductedTxt>Investments</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>INVESTMENTS</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>8461823</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <OfficesCnt>2</OfficesCnt>
        <EmployeeCnt>2</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>Program Services</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>RESEARCH SUPPORT</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>375453</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>East Asia and the Pacific</RegionTxt>
        <TypeOfActivitiesConductedTxt>Grantmaking</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>RESEARCH GRANTS</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>3734400</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>Middle East and North Africa</RegionTxt>
        <TypeOfActivitiesConductedTxt>Grantmaking</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>RESEARCH GRANTS</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>1472215</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <TypeOfActivitiesConductedTxt>Grantmaking</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>RESEARCH GRANTS</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>13479221</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <SubtotalOfficesCnt>2</SubtotalOfficesCnt>
      <SubtotalEmployeesCnt>2</SubtotalEmployeesCnt>
      <TotalOfficeCnt>2</TotalOfficeCnt>
      <TotalEmployeeCnt>2</TotalEmployeeCnt>
      <SubtotalSpentAmt>31828112</SubtotalSpentAmt>
      <TotalSpentAmt>31828112</TotalSpentAmt>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>50000</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>North America</RegionTxt>
        <CashGrantAmt>61847</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Middle East and North Africa</RegionTxt>
        <CashGrantAmt>770360</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <CashGrantAmt>777248</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Middle East and North Africa</RegionTxt>
        <CashGrantAmt>250748</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <CashGrantAmt>907009</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>East Asia and the Pacific</RegionTxt>
        <CashGrantAmt>197513</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>East Asia and the Pacific</RegionTxt>
        <CashGrantAmt>468226</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>North America</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>483604</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <CashGrantAmt>63388</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>East Asia and the Pacific</RegionTxt>
        <CashGrantAmt>145000</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>North America</RegionTxt>
        <CashGrantAmt>488106</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>North America</RegionTxt>
        <CashGrantAmt>923269</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>508049</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>441922</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <CashGrantAmt>249673</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>North America</RegionTxt>
        <CashGrantAmt>436051</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <CashGrantAmt>931478</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <CashGrantAmt>248798</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>378465</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>East Asia and the Pacific</RegionTxt>
        <CashGrantAmt>333716</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>110000</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>100000</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>650000</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>North America</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>190250</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <CashGrantAmt>379999</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>North America</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>1000000</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>East Asia and the Pacific</RegionTxt>
        <CashGrantAmt>1199144</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>North America</RegionTxt>
        <CashGrantAmt>62640</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>149432</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>331590</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <CashGrantAmt>149614</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <CashGrantAmt>691243</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <CashGrantAmt>169358</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>North America</RegionTxt>
        <CashGrantAmt>92277</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>East Asia and the Pacific</RegionTxt>
        <PurposeOfGrantTxt>ARTIFICIAL PANCREAS</PurposeOfGrantTxt>
        <CashGrantAmt>250000</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <CashGrantAmt>232580</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <CashGrantAmt>2007864</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THEPAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>440766</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <CashGrantAmt>265937</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>229626</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>East Asia and the Pacific</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>150000</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <CashGrantAmt>388107</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Middle East and North Africa</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>451867</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>East Asia and the Pacific</RegionTxt>
        <CashGrantAmt>250000</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>North America</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>367768</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <CashGrantAmt>681170</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <CashGrantAmt>249694</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>BETA CELL</PurposeOfGrantTxt>
        <CashGrantAmt>125000</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>PREVENTION</PurposeOfGrantTxt>
        <CashGrantAmt>90787</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>262419</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>BETA CELL</PurposeOfGrantTxt>
        <CashGrantAmt>65231</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>118496</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>North America</RegionTxt>
        <PurposeOfGrantTxt>COMPLICATIONS</PurposeOfGrantTxt>
        <CashGrantAmt>118639</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>East Asia and the Pacific</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>499993</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>79936</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>99532</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>BETA CELL</PurposeOfGrantTxt>
        <CashGrantAmt>125000</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>REGENERATION</PurposeOfGrantTxt>
        <CashGrantAmt>620000</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>East Asia and the Pacific</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>374920</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>North America</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>80550</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>232154</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>623261</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
        <CashGrantAmt>113157</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>IMMUNE THERAPPIES</PurposeOfGrantTxt>
        <CashGrantAmt>150000</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK/WIRE</MannerOfCashDisbursementTxt>
        <DescriptionOfNonCashAsstTxt>N/A</DescriptionOfNonCashAsstTxt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <Total501c3OrgCnt>50</Total501c3OrgCnt>
      <TotalOtherOrgCnt>15</TotalOtherOrgCnt>
      <TransferToForeignCorpInd>true</TransferToForeignCorpInd>
      <InterestInForeignTrustInd>false</InterestInForeignTrustInd>
      <ForeignCorpOwnershipInd>true</ForeignCorpOwnershipInd>
      <PassiveForeignInvestmestCoInd>true</PassiveForeignInvestmestCoInd>
      <ForeignPartnershipInd>false</ForeignPartnershipInd>
      <BoycottCountriesInd>false</BoycottCountriesInd>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>GRANT MONITORING PROCEDURES</FormAndLineReferenceDesc>
        <ExplanationTxt>SCH-F PART I LINE 2 Research grants are awarded by JDRFs Research Committee comprised of "JDRF Board members and other volunteers" following the recommendations of an in-house team of professional scientific staff and with input from external scientific reviewers and patient advocates. The review process includes the following criteria: (1) The scientific merit of the proposed research outlined in a grant application and (2) The relationship of the proposed research to JDRFs goal to cure, prevent and treat T1D and its complications. The scientific research team and grant administration staff maintain close contact with grantees, providing advice, evaluation, research progress reports, helping disseminate research results and reviewing research expenditures versus agreed budgets.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleF>
    <IRS990ScheduleG documentId="IRS990ScheduleG">
      <MailSolicitationsInd>X</MailSolicitationsInd>
      <EmailSolicitationsInd>X</EmailSolicitationsInd>
      <SolicitationOfNonGovtGrantsInd>X</SolicitationOfNonGovtGrantsInd>
      <SolicitationOfGovtGrantsInd>X</SolicitationOfGovtGrantsInd>
      <SpecialFundraisingEventsInd>X</SpecialFundraisingEventsInd>
      <AgrmtProfFundraisingActyInd>true</AgrmtProfFundraisingActyInd>
      <FundraiserActivityInfoGrp>
        <PersonNm>Insurance Auto Auctions</PersonNm>
        <USAddress>
          <AddressLine1Txt>PO Box 2365</AddressLine1Txt>
          <CityNm>Fair Oaks</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>95628</ZIPCd>
        </USAddress>
        <ActivityTxt>CAR DONATION</ActivityTxt>
        <FundraiserControlOfFundsInd>true</FundraiserControlOfFundsInd>
        <GrossReceiptsAmt>260800</GrossReceiptsAmt>
        <RetainedByContractorAmt>95118</RetainedByContractorAmt>
        <NetToOrganizationAmt>165682</NetToOrganizationAmt>
      </FundraiserActivityInfoGrp>
      <TotalGrossReceiptsAmt>260800</TotalGrossReceiptsAmt>
      <TotalRetainedByContractorsAmt>95118</TotalRetainedByContractorsAmt>
      <TotalNetToOrganizationAmt>165682</TotalNetToOrganizationAmt>
      <LicensedStatesCd>AL</LicensedStatesCd>
      <LicensedStatesCd>AK</LicensedStatesCd>
      <LicensedStatesCd>AZ</LicensedStatesCd>
      <LicensedStatesCd>AR</LicensedStatesCd>
      <LicensedStatesCd>CA</LicensedStatesCd>
      <LicensedStatesCd>CO</LicensedStatesCd>
      <LicensedStatesCd>CT</LicensedStatesCd>
      <LicensedStatesCd>DE</LicensedStatesCd>
      <LicensedStatesCd>DC</LicensedStatesCd>
      <LicensedStatesCd>FL</LicensedStatesCd>
      <LicensedStatesCd>GA</LicensedStatesCd>
      <LicensedStatesCd>HI</LicensedStatesCd>
      <LicensedStatesCd>ID</LicensedStatesCd>
      <LicensedStatesCd>IL</LicensedStatesCd>
      <LicensedStatesCd>IN</LicensedStatesCd>
      <LicensedStatesCd>IA</LicensedStatesCd>
      <LicensedStatesCd>KS</LicensedStatesCd>
      <LicensedStatesCd>KY</LicensedStatesCd>
      <LicensedStatesCd>LA</LicensedStatesCd>
      <LicensedStatesCd>ME</LicensedStatesCd>
      <LicensedStatesCd>MD</LicensedStatesCd>
      <LicensedStatesCd>MA</LicensedStatesCd>
      <LicensedStatesCd>MI</LicensedStatesCd>
      <LicensedStatesCd>MN</LicensedStatesCd>
      <LicensedStatesCd>MS</LicensedStatesCd>
      <LicensedStatesCd>MO</LicensedStatesCd>
      <LicensedStatesCd>MT</LicensedStatesCd>
      <LicensedStatesCd>NE</LicensedStatesCd>
      <LicensedStatesCd>NV</LicensedStatesCd>
      <LicensedStatesCd>NH</LicensedStatesCd>
      <LicensedStatesCd>NJ</LicensedStatesCd>
      <LicensedStatesCd>NM</LicensedStatesCd>
      <LicensedStatesCd>NY</LicensedStatesCd>
      <LicensedStatesCd>NC</LicensedStatesCd>
      <LicensedStatesCd>ND</LicensedStatesCd>
      <LicensedStatesCd>OH</LicensedStatesCd>
      <LicensedStatesCd>OK</LicensedStatesCd>
      <LicensedStatesCd>OR</LicensedStatesCd>
      <LicensedStatesCd>PA</LicensedStatesCd>
      <LicensedStatesCd>RI</LicensedStatesCd>
      <LicensedStatesCd>SC</LicensedStatesCd>
      <LicensedStatesCd>SD</LicensedStatesCd>
      <LicensedStatesCd>TN</LicensedStatesCd>
      <LicensedStatesCd>TX</LicensedStatesCd>
      <LicensedStatesCd>UT</LicensedStatesCd>
      <LicensedStatesCd>VT</LicensedStatesCd>
      <LicensedStatesCd>VA</LicensedStatesCd>
      <LicensedStatesCd>WA</LicensedStatesCd>
      <LicensedStatesCd>WV</LicensedStatesCd>
      <LicensedStatesCd>WI</LicensedStatesCd>
      <LicensedStatesCd>WY</LicensedStatesCd>
      <FundraisingEventInformationGrp>
        <Event1Nm>SEATTLE GALA</Event1Nm>
        <GrossReceiptsEvent1Amt>2651726</GrossReceiptsEvent1Amt>
        <CharitableContriEvent1Amt>1970220</CharitableContriEvent1Amt>
        <GrossRevenueEvent1Amt>681506</GrossRevenueEvent1Amt>
        <NonCashPrizesEvent1Amt>17308</NonCashPrizesEvent1Amt>
        <RentFacilityCostsEvent1Amt>216426</RentFacilityCostsEvent1Amt>
        <FoodAndBeverageEvent1Amt>15310</FoodAndBeverageEvent1Amt>
        <EntertainmentEvent1Amt>242509</EntertainmentEvent1Amt>
        <OtherDirectExpensesEvent1Amt>64290</OtherDirectExpensesEvent1Amt>
        <Event2Nm>ILLINOIS GALA</Event2Nm>
        <GrossReceiptsEvent2Amt>4927110</GrossReceiptsEvent2Amt>
        <CharitableContriEvent2Amt>4228565</CharitableContriEvent2Amt>
        <GrossRevenueEvent2Amt>698545</GrossRevenueEvent2Amt>
        <RentFacilityCostsEvent2Amt>40547</RentFacilityCostsEvent2Amt>
        <FoodAndBeverageEvent2Amt>230419</FoodAndBeverageEvent2Amt>
        <EntertainmentEvent2Amt>318066</EntertainmentEvent2Amt>
        <OtherDirectExpensesEvent2Amt>9364</OtherDirectExpensesEvent2Amt>
        <OtherEventsTotalCnt>375</OtherEventsTotalCnt>
        <GrossReceiptsOtherEventsAmt>147245819</GrossReceiptsOtherEventsAmt>
        <CharitableContriOtherEventsAmt>121472897</CharitableContriOtherEventsAmt>
        <GrossRevenueOtherEventsAmt>25772922</GrossRevenueOtherEventsAmt>
        <NonCashPrizesOtherEventsAmt>79306</NonCashPrizesOtherEventsAmt>
        <RentFcltyCostsOtherEventsAmt>3435039</RentFcltyCostsOtherEventsAmt>
        <FoodAndBeverageOtherEventsAmt>2529307</FoodAndBeverageOtherEventsAmt>
        <EntertainmentOtherEventsAmt>3373875</EntertainmentOtherEventsAmt>
        <OthDirectExpnssOtherEventsAmt>16581207</OthDirectExpnssOtherEventsAmt>
        <GrossReceiptsTotalAmt>154824655</GrossReceiptsTotalAmt>
        <CharitableContributionsTotAmt>127671682</CharitableContributionsTotAmt>
        <GrossRevenueTotalEventsAmt>27152973</GrossRevenueTotalEventsAmt>
        <NonCashPrizesTotalEventsAmt>96614</NonCashPrizesTotalEventsAmt>
        <RentFcltyCostsTotalEventsAmt>3692012</RentFcltyCostsTotalEventsAmt>
        <FoodAndBeverageTotalEventsAmt>2775036</FoodAndBeverageTotalEventsAmt>
        <EntertainmentTotalEventsAmt>3934450</EntertainmentTotalEventsAmt>
        <OthDirectExpnssTotalEventsAmt>16654861</OthDirectExpnssTotalEventsAmt>
        <DirectExpenseSummaryEventsAmt>27152973</DirectExpenseSummaryEventsAmt>
      </FundraisingEventInformationGrp>
      <GamingInformationGrp>
        <GrossRevenueOtherGamingAmt>1106452</GrossRevenueOtherGamingAmt>
        <CashPrizesOtherGamingAmt>10000</CashPrizesOtherGamingAmt>
        <NonCashPrizesOtherGamingAmt>249790</NonCashPrizesOtherGamingAmt>
        <VolunteerLaborOtherGamingInd>false</VolunteerLaborOtherGamingInd>
        <GrossRevenueTotalGamingAmt>1106452</GrossRevenueTotalGamingAmt>
        <CashPrizesTotalGamingAmt>10000</CashPrizesTotalGamingAmt>
        <NonCashPrizesTotalGamingAmt>249790</NonCashPrizesTotalGamingAmt>
        <DirectExpenseSummaryGamingAmt>259790</DirectExpenseSummaryGamingAmt>
        <NetGamingIncomeSummaryAmt>846662</NetGamingIncomeSummaryAmt>
      </GamingInformationGrp>
      <StatesWhereGamingConductedCd>AL</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>AK</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>AZ</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>AR</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>CA</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>CO</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>CT</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>DE</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>DC</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>FL</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>GA</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>HI</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>ID</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>IL</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>IN</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>IA</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>KS</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>KY</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>LA</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>ME</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>MD</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>MA</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>MI</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>MN</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>MS</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>MO</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>MT</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>NE</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>NV</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>NH</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>NJ</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>NM</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>NY</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>NC</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>ND</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>OH</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>OK</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>OR</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>PA</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>RI</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>SC</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>SD</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>TN</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>TX</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>UT</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>VT</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>VA</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>WA</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>WV</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>WI</StatesWhereGamingConductedCd>
      <StatesWhereGamingConductedCd>WY</StatesWhereGamingConductedCd>
      <LicensedInd>true</LicensedInd>
      <LicenseSuspendedEtcInd>false</LicenseSuspendedEtcInd>
      <GamingWithNonmembersInd>false</GamingWithNonmembersInd>
      <MemberOfOtherEntityInd>false</MemberOfOtherEntityInd>
      <GamingOtherFacilityPct>1.00000</GamingOtherFacilityPct>
      <IndividualWithBooksNm>GARY CURTO</IndividualWithBooksNm>
      <PersonsWithBooksUSAddress>
        <AddressLine1Txt>26 BROADWAY-14TH FLOOR</AddressLine1Txt>
        <CityNm>NEW YORK</CityNm>
        <StateAbbreviationCd>NY</StateAbbreviationCd>
        <ZIPCd>10004</ZIPCd>
      </PersonsWithBooksUSAddress>
      <CntrctWith3rdPrtyForGameRevInd>false</CntrctWith3rdPrtyForGameRevInd>
      <GamingManagerPersonNm>GARY CURTO TAX MANAGER -JDRF</GamingManagerPersonNm>
      <GamingManagerCompensationAmt>0</GamingManagerCompensationAmt>
      <GamingManagerServicesProvTxt>FILING GAMING APPLICATIONS AND REPORTS</GamingManagerServicesProvTxt>
      <GamingManagerIsEmployeeInd>X</GamingManagerIsEmployeeInd>
      <CharitableDistributionRqrInd>true</CharitableDistributionRqrInd>
      <DistributedAmt>846662</DistributedAmt>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>SCHEDULE G, PART I, LINE 2</FormAndLineReferenceDesc>
        <ExplanationTxt>INSURANCE AUTO AUCTIONS LLC IS A STATE LICENSED PROFESSIONAL FUNDRAISER THAT HANDLES ALL ASPECTS OF CARS BEING DONATED TO JDRF. DONORS CONTACT THE COMPANY DIRECTLY THROUGH A TOLL FREE NUMBER TO COORDINATE THE DONATION, FOLLOWING WHICH INSURANCE AUTO AUCTIONS HANDLES ALL REQUIRED IRS 1098C REPORTING. FOR THE PERIOD ENDING 6/30/17, THE CAR PROGRAM RAISED $260,800 WITH TOTAL EXPENSES OF $95,118 WITH THE NET PROCEEDS OF $165,682 PROVIDED DIRECTLY TO JDRF. JDRF PAYS NO ADDITIONAL EXPENSES OR FEES TO INSURANCE AUTO AUCTIONS FOR THIS PROGRAM.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleG>
    <IRS990ScheduleI documentId="IRS990ScheduleI">
      <GrantRecordsMaintainedInd>true</GrantRecordsMaintainedInd>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>BENAROYA RESEARCH INST AT VIRGINIA MASON</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1201 9TH AVE</AddressLine1Txt>
          <CityNm>SEATTLE</CityNm>
          <StateAbbreviationCd>WA</StateAbbreviationCd>
          <ZIPCd>98101</ZIPCd>
        </USAddress>
        <RecipientEIN>910653422</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>2691474</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>BD TECHNOLOGIES</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>DAVIS DRIVE</AddressLine1Txt>
          <CityNm>RESEARCH TRIANGLE PK</CityNm>
          <StateAbbreviationCd>NC</StateAbbreviationCd>
          <ZIPCd>27709</ZIPCd>
        </USAddress>
        <RecipientEIN>999999999</RecipientEIN>
        <CashGrantAmt>400000</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>ANN AND ROBERT LURIE CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>320 NORTH AVE</AddressLine1Txt>
          <CityNm>PITTSBURGH</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>15212</ZIPCd>
        </USAddress>
        <RecipientEIN>362170833</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>10000</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>CAPILLARY BIOMEDICAL</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>56 HAVENWOOD</AddressLine1Txt>
          <CityNm>IRVINE</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>92614</ZIPCd>
        </USAddress>
        <RecipientEIN>464787731</RecipientEIN>
        <CashGrantAmt>130000</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>CASE WESTERN UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>10900 EUCLID AVE</AddressLine1Txt>
          <CityNm>CLEVELAND</CityNm>
          <StateAbbreviationCd>OH</StateAbbreviationCd>
          <ZIPCd>44106</ZIPCd>
        </USAddress>
        <RecipientEIN>341018992</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>170816</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF ARIZONA</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>PO BOX 210</AddressLine1Txt>
          <CityNm>TUCSON</CityNm>
          <StateAbbreviationCd>AZ</StateAbbreviationCd>
          <ZIPCd>85721</ZIPCd>
        </USAddress>
        <RecipientEIN>113661893</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>649113</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>CHILDREN'S HOSPITAL OF PHILADELPHIA</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>3401 CIVIC CENTER BLVD</AddressLine1Txt>
          <CityNm>PHIL</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>19014</ZIPCd>
        </USAddress>
        <RecipientEIN>231352166</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>108555</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>CRITICAL PATH INSTITUTE</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1730 EAST RIVER ROAD</AddressLine1Txt>
          <CityNm>TUCSON</CityNm>
          <StateAbbreviationCd>AZ</StateAbbreviationCd>
          <ZIPCd>85718</ZIPCd>
        </USAddress>
        <RecipientEIN>201991334</RecipientEIN>
        <CashGrantAmt>124000</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>INDIANA UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>620 UNION DR</AddressLine1Txt>
          <CityNm>INDIANAPOLIS</CityNm>
          <StateAbbreviationCd>IN</StateAbbreviationCd>
          <ZIPCd>46202</ZIPCd>
        </USAddress>
        <RecipientEIN>356018940</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>1072836</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>BETH ISRAEL MEDICAL CENTER</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1 BROOKLINE AVE</AddressLine1Txt>
          <CityNm>BOSTON</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>92121</ZIPCd>
        </USAddress>
        <RecipientEIN>135564934</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>506572</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>JOSLIN DIABETES CENTER</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1 JOSLIN PL</AddressLine1Txt>
          <CityNm>BOSTON</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02215</ZIPCd>
        </USAddress>
        <RecipientEIN>042203836</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>1109271</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>MASSACHUSETTS INSTITUTE OF TECHNOLOGY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>25 AMES ST</AddressLine1Txt>
          <CityNm>CAMBRIDGE</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02467</ZIPCd>
        </USAddress>
        <RecipientEIN>042103594</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>815502</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>INDIANA BIOSCIENCES RES INST</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1345 W 16TH STREET</AddressLine1Txt>
          <CityNm>INDIANAPOLIS</CityNm>
          <StateAbbreviationCd>IN</StateAbbreviationCd>
          <ZIPCd>46202</ZIPCd>
        </USAddress>
        <RecipientEIN>462882271</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>150000</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>CALIFORNIA INST FOR BIOMEDICAL RESEARCH</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>11119 NTORRY PINES RD</AddressLine1Txt>
          <CityNm>LAJOLLA</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>92037</ZIPCd>
        </USAddress>
        <RecipientEIN>956047739</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>2851029</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>EMORY UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>69 JESSE HILL JR DRIVE</AddressLine1Txt>
          <CityNm>ATLANTA</CityNm>
          <StateAbbreviationCd>GA</StateAbbreviationCd>
          <ZIPCd>30322</ZIPCd>
        </USAddress>
        <RecipientEIN>580566256</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>490526</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>MAYO CLINIC</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1216 2ND STREET</AddressLine1Txt>
          <CityNm>ROCHESTER</CityNm>
          <StateAbbreviationCd>MN</StateAbbreviationCd>
          <ZIPCd>55902</ZIPCd>
        </USAddress>
        <RecipientEIN>411405254</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>326202</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>GEORGIA TECH RESEARCH CORP</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>505 TENTH STREET</AddressLine1Txt>
          <CityNm>ATLANTA</CityNm>
          <StateAbbreviationCd>GA</StateAbbreviationCd>
          <ZIPCd>30332</ZIPCd>
        </USAddress>
        <RecipientEIN>580603146</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>180695</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>STANFORD UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>300 PASTEUR DR</AddressLine1Txt>
          <CityNm>PALA ALTO</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>94305</ZIPCd>
        </USAddress>
        <RecipientEIN>941156365</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>772523</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>JOHNS HOPKINS UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>733 N BROADWAY</AddressLine1Txt>
          <CityNm>BALTIMORE</CityNm>
          <StateAbbreviationCd>MD</StateAbbreviationCd>
          <ZIPCd>21205</ZIPCd>
        </USAddress>
        <RecipientEIN>520595110</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>499991</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>NEW YORK UNIVERSITY SCHOOL OF MEDICINE</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>550 FIRST AVENUE</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10016</ZIPCd>
        </USAddress>
        <RecipientEIN>135562309</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>510000</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>NATIONAL JEWISH HEALTH</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>601 EAST 18TH STREET</AddressLine1Txt>
          <CityNm>DENVER</CityNm>
          <StateAbbreviationCd>CO</StateAbbreviationCd>
          <ZIPCd>80206</ZIPCd>
        </USAddress>
        <RecipientEIN>742044647</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>250000</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>NORTH CAROLINA STATE UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>2701 SULLIVAN DRIVE</AddressLine1Txt>
          <CityNm>RALEIGH</CityNm>
          <StateAbbreviationCd>NC</StateAbbreviationCd>
          <ZIPCd>27695</ZIPCd>
        </USAddress>
        <RecipientEIN>440680117</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>540000</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>NEW YORK STEM CELL FOUNDATION</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>619 WEST 54TH STREET</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10019</ZIPCd>
        </USAddress>
        <RecipientEIN>202905531</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>200000</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>BECKMAN RESEARCH INST OF THE CITY OF HOPE</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1500 EAST DUARTE ROAD</AddressLine1Txt>
          <CityNm>DUARTE</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>91010</ZIPCd>
        </USAddress>
        <RecipientEIN>953432210</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>1171777</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>OREGON HEALTH &amp; SCIENCE UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>3181 SW SAM JACKSON</AddressLine1Txt>
          <CityNm>PORTLAND</CityNm>
          <StateAbbreviationCd>OR</StateAbbreviationCd>
          <ZIPCd>97239</ZIPCd>
        </USAddress>
        <RecipientEIN>237083114</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>464937</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>LEXICON PHARMACEUTICALS</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>8800 TECH FOREST PL</AddressLine1Txt>
          <CityNm>THE WOODLANDS</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>77381</ZIPCd>
        </USAddress>
        <RecipientEIN>760474179</RecipientEIN>
        <CashGrantAmt>400000</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>PACIFIC DIABETES TECHNOLOGIES</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>12154 SW GARDEN PLACE</AddressLine1Txt>
          <CityNm>PORTLAND</CityNm>
          <StateAbbreviationCd>OR</StateAbbreviationCd>
          <ZIPCd>97223</ZIPCd>
        </USAddress>
        <RecipientEIN>999999999</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>178788</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF FLORIDA</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1600 SW ARCHER ROAD</AddressLine1Txt>
          <CityNm>GAINESVILLE</CityNm>
          <StateAbbreviationCd>FL</StateAbbreviationCd>
          <ZIPCd>32610</ZIPCd>
        </USAddress>
        <RecipientEIN>590974739</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>3291730</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>55 LAKE AVE NORTH</AddressLine1Txt>
          <CityNm>WORCESTER</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>01605</ZIPCd>
        </USAddress>
        <RecipientEIN>043167352</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>70815</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF MIAMI SCHOOL OF MEDICINE</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1450 NW 10TH AVE</AddressLine1Txt>
          <CityNm>MIAMI</CityNm>
          <StateAbbreviationCd>FL</StateAbbreviationCd>
          <ZIPCd>33136</ZIPCd>
        </USAddress>
        <RecipientEIN>590624458</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>1967148</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF VIRGINIA</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>104 MIDMONT LN</AddressLine1Txt>
          <CityNm>CHARLOTTESVILLE</CityNm>
          <StateAbbreviationCd>VA</StateAbbreviationCd>
          <ZIPCd>22902</ZIPCd>
        </USAddress>
        <RecipientEIN>416042488</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>334651</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF MICHIGAN</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1331 EAST ANN STREET</AddressLine1Txt>
          <CityNm>ANN ARBOR</CityNm>
          <StateAbbreviationCd>MI</StateAbbreviationCd>
          <ZIPCd>48109</ZIPCd>
        </USAddress>
        <RecipientEIN>386006309</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>894233</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>PACIFIC NORTHWEST RESEARCH INSTITUTE</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>720 BROADWAY</AddressLine1Txt>
          <CityNm>SEATTLE</CityNm>
          <StateAbbreviationCd>WA</StateAbbreviationCd>
          <ZIPCd>98122</ZIPCd>
        </USAddress>
        <RecipientEIN>910667886</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>40233</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>TETRAGENETICS</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>91 MYSTIC STREET</AddressLine1Txt>
          <CityNm>ARLINGTON</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02474</ZIPCd>
        </USAddress>
        <RecipientEIN>043784099</RecipientEIN>
        <CashGrantAmt>710000</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF CALIFORNIA</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>3333 CA ST</AddressLine1Txt>
          <CityNm>SAN FRANCISCO</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>94122</ZIPCd>
        </USAddress>
        <RecipientEIN>956006143</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>5968555</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF WISCONSIN-MADISON</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>21 NORTH PARK</AddressLine1Txt>
          <CityNm>MADISON</CityNm>
          <StateAbbreviationCd>WI</StateAbbreviationCd>
          <ZIPCd>53706</ZIPCd>
        </USAddress>
        <RecipientEIN>396006492</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>650000</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UT SOUTHWESTERN MEDICAL CENTER</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>5323 HARRY HINES BLVD</AddressLine1Txt>
          <CityNm>DALLAS</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>75390</ZIPCd>
        </USAddress>
        <RecipientEIN>756002868</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>738690</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1211 MEDICAL CENTER DR</AddressLine1Txt>
          <CityNm>NASHVILLE</CityNm>
          <StateAbbreviationCd>TN</StateAbbreviationCd>
          <ZIPCd>37232</ZIPCd>
        </USAddress>
        <RecipientEIN>620476822</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>388079</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>BAYLOR COLLEGE OF MEDICINE-RESEARCH INSTITUTE</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>3500 GASTON AVE</AddressLine1Txt>
          <CityNm>DALLAS</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>75246</ZIPCd>
        </USAddress>
        <RecipientEIN>751921898</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>246356</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>BROAD INSTITUTE</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>7 CAMBRIDGE CENTER</AddressLine1Txt>
          <CityNm>CAMBRIDGE</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02142</ZIPCd>
        </USAddress>
        <RecipientEIN>263428781</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>285342</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>DUKE UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>4321 MEDICAL PARK DR</AddressLine1Txt>
          <CityNm>DURHAM</CityNm>
          <StateAbbreviationCd>NC</StateAbbreviationCd>
          <ZIPCd>27704</ZIPCd>
        </USAddress>
        <RecipientEIN>560532129</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>368992</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF CONNECTICUT</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>69 N EAGLEVILLE</AddressLine1Txt>
          <CityNm>STORRS</CityNm>
          <StateAbbreviationCd>CT</StateAbbreviationCd>
          <ZIPCd>06269</ZIPCd>
        </USAddress>
        <RecipientEIN>066085975</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>249999</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF SOUTH FLORIDA</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>4202 E FOWLER AVE</AddressLine1Txt>
          <CityNm>TAMPA</CityNm>
          <StateAbbreviationCd>FL</StateAbbreviationCd>
          <ZIPCd>33620</ZIPCd>
        </USAddress>
        <RecipientEIN>590879015</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>423532</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FND</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>15310 Amberly Drive</AddressLine1Txt>
          <CityNm>TAMPA</CityNm>
          <StateAbbreviationCd>FL</StateAbbreviationCd>
          <ZIPCd>33647</ZIPCd>
        </USAddress>
        <RecipientEIN>593187624</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>3950383</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>VIACYTE</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>3550 GENERAL ATOMICS</AddressLine1Txt>
          <CityNm>SAN DIEGO</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>92121</ZIPCd>
        </USAddress>
        <RecipientEIN>330884172</RecipientEIN>
        <CashGrantAmt>2000000</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>COLUMBIA UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>PO BOX 29789</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10087</ZIPCd>
        </USAddress>
        <RecipientEIN>135598093</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>327912</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>YALE UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>PO BOX 209010</AddressLine1Txt>
          <CityNm>NEW HAVEN</CityNm>
          <StateAbbreviationCd>CT</StateAbbreviationCd>
          <ZIPCd>06520</ZIPCd>
        </USAddress>
        <RecipientEIN>060646973</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>861255</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF ALABAMA</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>COLLEGE DRIVE</AddressLine1Txt>
          <CityNm>BIRMINGHAM</CityNm>
          <StateAbbreviationCd>AL</StateAbbreviationCd>
          <ZIPCd>35294</ZIPCd>
        </USAddress>
        <RecipientEIN>636001138</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>627092</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>NORTHWESTERN UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>633 CLARK STREET</AddressLine1Txt>
          <CityNm>EVANSTON</CityNm>
          <StateAbbreviationCd>IL</StateAbbreviationCd>
          <ZIPCd>60208</ZIPCd>
        </USAddress>
        <RecipientEIN>231352685</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>922961</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>DANA-FARBER CANCER INSTITUTE</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>450 BROOKLINE AVE</AddressLine1Txt>
          <CityNm>BOSTON</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02115</ZIPCd>
        </USAddress>
        <RecipientEIN>042263040</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>60816</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>BETA CELL THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>SELECTA BIOSCIENCE INC</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>480 ARSENAL STREET</AddressLine1Txt>
          <CityNm>WATERTOWN</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02472</ZIPCd>
        </USAddress>
        <RecipientEIN>261622110</RecipientEIN>
        <CashGrantAmt>47879</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>THE UNIVERSITY OF CHICAGO</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>5801 SOUTH ELLIS AVE</AddressLine1Txt>
          <CityNm>CHICAGO</CityNm>
          <StateAbbreviationCd>IL</StateAbbreviationCd>
          <ZIPCd>60637</ZIPCd>
        </USAddress>
        <RecipientEIN>362177139</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>249998</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE MOUNT SINAI</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1 GUSTAVE L LEVY PLACE</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10029</ZIPCd>
        </USAddress>
        <RecipientEIN>136171197</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>637698</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>NOVARTIS INSTITUTE-GENOMICS</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>10675 JOHN HOPKINS DR</AddressLine1Txt>
          <CityNm>SAN DIEGO</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>92121</ZIPCd>
        </USAddress>
        <RecipientEIN>223610512</RecipientEIN>
        <CashGrantAmt>504565</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>ILLINOIS INSTITUTE OF TECHNOLOGY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>3300 SOUTH FEDERAL STREET</AddressLine1Txt>
          <CityNm>CHICAGO</CityNm>
          <StateAbbreviationCd>IL</StateAbbreviationCd>
          <ZIPCd>60616</ZIPCd>
        </USAddress>
        <RecipientEIN>362170136</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>246082</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>80 SOUTH 8TH STREET</AddressLine1Txt>
          <CityNm>MINNEAPOLIS</CityNm>
          <StateAbbreviationCd>MN</StateAbbreviationCd>
          <ZIPCd>55455</ZIPCd>
        </USAddress>
        <RecipientEIN>416007513</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>1149643</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>JACKSON LABORATORY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>600 MAIN STREET</AddressLine1Txt>
          <CityNm>BAR HARBOR</CityNm>
          <StateAbbreviationCd>ME</StateAbbreviationCd>
          <ZIPCd>04609</ZIPCd>
        </USAddress>
        <RecipientEIN>010211513</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>62640</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>RUTGERS THE STATE UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>175 UNIVERSITY AVE</AddressLine1Txt>
          <CityNm>NEWARK</CityNm>
          <StateAbbreviationCd>NJ</StateAbbreviationCd>
          <ZIPCd>07107</ZIPCd>
        </USAddress>
        <RecipientEIN>462354111</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>347735</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF WASHINGTON</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1401 15TH AVE</AddressLine1Txt>
          <CityNm>SEATTLE</CityNm>
          <StateAbbreviationCd>WA</StateAbbreviationCd>
          <ZIPCd>98195</ZIPCd>
        </USAddress>
        <RecipientEIN>911486484</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>543444</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>WESTERN MICHIGAN UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1903 W MICHIGAN ANE</AddressLine1Txt>
          <CityNm>KALAMAZOO</CityNm>
          <StateAbbreviationCd>MI</StateAbbreviationCd>
          <ZIPCd>49008</ZIPCd>
        </USAddress>
        <RecipientEIN>454135256</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>127088</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>CLEMSON UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>105 COLLINGS ST</AddressLine1Txt>
          <CityNm>CLEMSON</CityNm>
          <StateAbbreviationCd>SC</StateAbbreviationCd>
          <ZIPCd>29634</ZIPCd>
        </USAddress>
        <RecipientEIN>157600025</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>10000</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>PREVENTION</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>DIABETOMICS</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>2345 AMBERBROOK</AddressLine1Txt>
          <CityNm>HILLSBORO</CityNm>
          <StateAbbreviationCd>OR</StateAbbreviationCd>
          <ZIPCd>97006</ZIPCd>
        </USAddress>
        <RecipientEIN>273132477</RecipientEIN>
        <CashGrantAmt>90000</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>PREVENTION</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>OHIO STATE UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>281 W Lane AVE</AddressLine1Txt>
          <CityNm>COLUMBUS</CityNm>
          <StateAbbreviationCd>OH</StateAbbreviationCd>
          <ZIPCd>43210</ZIPCd>
        </USAddress>
        <RecipientEIN>611730890</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>140000</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>ARTIFICIAL PANCREAS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>THE BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
          <CityNm>BOSTON</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02115</ZIPCd>
        </USAddress>
        <RecipientEIN>042312909</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>164996</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>COMPLICATIONS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>THOMAS JEFFERSON UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>125 S 9TH STREET</AddressLine1Txt>
          <CityNm>PHILADELPHIA</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>19019</ZIPCd>
        </USAddress>
        <RecipientEIN>232829095</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>110000</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>ARTIFICIAL PANCREAS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>TIDEPOOL</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>450 TOWNSEND ST</AddressLine1Txt>
          <CityNm>SAN FRANCISCO</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>94107</ZIPCd>
        </USAddress>
        <RecipientEIN>462302287</RecipientEIN>
        <CashGrantAmt>2076155</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>ARTIFICIAL PANCREAS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>WAVE 80 BIOSCIENCES</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>2325 THIRD STREET</AddressLine1Txt>
          <CityNm>SAN FRANCISCO</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>94107</ZIPCd>
        </USAddress>
        <RecipientEIN>020691818</RecipientEIN>
        <CashGrantAmt>80000</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>PREVENTION</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF UTAH</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>201 PRESIDENTS CR</AddressLine1Txt>
          <CityNm>SALT LAKE CITY</CityNm>
          <StateAbbreviationCd>UT</StateAbbreviationCd>
          <ZIPCd>84102</ZIPCd>
        </USAddress>
        <RecipientEIN>876000525</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>858631</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>GLUCOSE MODULATION</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>WAYNE STATE UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>5700 CASS AVE</AddressLine1Txt>
          <CityNm>DETROIT</CityNm>
          <StateAbbreviationCd>MI</StateAbbreviationCd>
          <ZIPCd>48201</ZIPCd>
        </USAddress>
        <RecipientEIN>383555142</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>269856</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>ENCAPSULATED ISLETS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>ALLEGHENY SINGER RESEARCH INST</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>320 E NORTH AVENUE</AddressLine1Txt>
          <CityNm>PITTSBURGH</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>15212</ZIPCd>
        </USAddress>
        <RecipientEIN>251320493</RecipientEIN>
        <CashGrantAmt>249999</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>BETA CELL THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>HARVARD MEDICAL SCHOOL</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>200 LONGWOOD AVE</AddressLine1Txt>
          <CityNm>BOSTON</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02115</ZIPCd>
        </USAddress>
        <RecipientEIN>042103580</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>883862</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>PRODO LABORATORIES</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>27402 ALISO VIEJO PKY</AddressLine1Txt>
          <CityNm>ALISO VIEJO</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>92656</ZIPCd>
        </USAddress>
        <RecipientEIN>205534494</RecipientEIN>
        <CashGrantAmt>36478</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>PROTOMER TECHNOLOGIES</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>430 S CATALINA AVE</AddressLine1Txt>
          <CityNm>PASADENA</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>91106</ZIPCd>
        </USAddress>
        <RecipientEIN>474206994</RecipientEIN>
        <CashGrantAmt>280000</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF SOUTHERN CALIFORNIA</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>COLLEGE DRIVE</AddressLine1Txt>
          <CityNm>LOS ANGELES</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>90089</ZIPCd>
        </USAddress>
        <RecipientEIN>951642394</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>362454</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF COLORADO</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>PO BOX 6511</AddressLine1Txt>
          <CityNm>DENVER</CityNm>
          <StateAbbreviationCd>CO</StateAbbreviationCd>
          <ZIPCd>80045</ZIPCd>
        </USAddress>
        <RecipientEIN>846049811</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>1490772</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF ILLINOIS</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1200 HARRISON</AddressLine1Txt>
          <CityNm>CHICAGO</CityNm>
          <StateAbbreviationCd>IL</StateAbbreviationCd>
          <ZIPCd>60612</ZIPCd>
        </USAddress>
        <RecipientEIN>376006007</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>236202</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNITIO</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>11 AVENUE DE LAYFETTE</AddressLine1Txt>
          <CityNm>BOSTON</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02111</ZIPCd>
        </USAddress>
        <RecipientEIN>451623549</RecipientEIN>
        <CashGrantAmt>491763</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF MARYLAND</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>COLLEGE PAR ROAD</AddressLine1Txt>
          <CityNm>COLLEGE PARK</CityNm>
          <StateAbbreviationCd>MD</StateAbbreviationCd>
          <ZIPCd>20737</ZIPCd>
        </USAddress>
        <RecipientEIN>522004514</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>524761</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF NEBRASKA</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>151 WHITTIER</AddressLine1Txt>
          <CityNm>LINCOLN</CityNm>
          <StateAbbreviationCd>NE</StateAbbreviationCd>
          <ZIPCd>68503</ZIPCd>
        </USAddress>
        <RecipientEIN>470379839</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>247021</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF TEXAS HEALTH SCIENCE</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>7703 FLOYD CURL DRIVE</AddressLine1Txt>
          <CityNm>SAN ANTONIO</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>78229</ZIPCd>
        </USAddress>
        <RecipientEIN>741586031</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>95000</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>WASHINGTON UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>One Brookings Drive</AddressLine1Txt>
          <CityNm>St Louis</CityNm>
          <StateAbbreviationCd>MO</StateAbbreviationCd>
          <ZIPCd>63130</ZIPCd>
        </USAddress>
        <RecipientEIN>430653611</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>708716</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF KANSAS CENTER FOR RESEARCH</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1200 SUNNYSIDE AVE</AddressLine1Txt>
          <CityNm>LAWRENCE</CityNm>
          <StateAbbreviationCd>KS</StateAbbreviationCd>
          <ZIPCd>66045</ZIPCd>
        </USAddress>
        <RecipientEIN>480680117</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>249997</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>IMMUNE THERAPIES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>AUGUSTA UNIVERSITY RESEARCH INSTITUTE</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1474 LANEY WALKER BLVD</AddressLine1Txt>
          <CityNm>AUGUSTA</CityNm>
          <StateAbbreviationCd>GA</StateAbbreviationCd>
          <ZIPCd>30912</ZIPCd>
        </USAddress>
        <RecipientEIN>581418202</RecipientEIN>
        <IRCSectionDesc>501(C)3</IRCSectionDesc>
        <CashGrantAmt>110889</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>BOSTON HEALTH ECONOMICS INC</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>222 BERKLEY STREET</AddressLine1Txt>
          <CityNm>BOSTON</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02116</ZIPCd>
        </USAddress>
        <RecipientEIN>043311183</RecipientEIN>
        <CashGrantAmt>242020</CashGrantAmt>
        <ValuationMethodUsedDesc>N/A</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>N/A</NonCashAssistanceDesc>
      </RecipientTable>
      <Total501c3OrgCnt>68</Total501c3OrgCnt>
      <TotalOtherOrgCnt>16</TotalOtherOrgCnt>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>GRANT MONITORING PROCEDURES</FormAndLineReferenceDesc>
        <ExplanationTxt>SCH-I PART I LINE 2 Research grants are awarded by JDRFs Research Committee comprised of "JDRF Board members and other volunteers" following the recommendations of an in-house team of professional scientific staff and with input from external scientific reviewers and patient advocates. The review process includes the following criteria: (1) The scientific merit of the proposed research outlined in a grant application and (2) The relationship of the proposed research to JDRFs goal to cure, prevent and treat T1D and its complications. The scientific research team and grant administration staff maintain close contact with grantees, providing advice, evaluation, research progress reports, helping disseminate research results and reviewing research expenditures versus agreed budgets.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleI>
    <IRS990ScheduleJ documentId="IRS990ScheduleJ">
      <HousingAllowanceOrResidenceInd>X</HousingAllowanceOrResidenceInd>
      <WrittenPolicyRefTAndEExpnssInd>true</WrittenPolicyRefTAndEExpnssInd>
      <SubstantiationRequiredInd>false</SubstantiationRequiredInd>
      <CompensationCommitteeInd>X</CompensationCommitteeInd>
      <IndependentConsultantInd>X</IndependentConsultantInd>
      <Form990OfOtherOrganizationsInd>X</Form990OfOtherOrganizationsInd>
      <CompensationSurveyInd>X</CompensationSurveyInd>
      <BoardOrCommitteeApprovalInd>X</BoardOrCommitteeApprovalInd>
      <SeverancePaymentInd>true</SeverancePaymentInd>
      <SupplementalNonqualRtrPlanInd>false</SupplementalNonqualRtrPlanInd>
      <EquityBasedCompArrngmInd>false</EquityBasedCompArrngmInd>
      <CompBasedOnRevenueOfFlngOrgInd>false</CompBasedOnRevenueOfFlngOrgInd>
      <CompBsdOnRevRelatedOrgsInd>false</CompBsdOnRevRelatedOrgsInd>
      <CompBsdNetEarnsFlngOrgInd>false</CompBsdNetEarnsFlngOrgInd>
      <CompBsdNetEarnsRltdOrgsInd>false</CompBsdNetEarnsRltdOrgsInd>
      <AnyNonFixedPaymentsInd>true</AnyNonFixedPaymentsInd>
      <InitialContractExceptionInd>false</InitialContractExceptionInd>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>DEREK RAPP</PersonNm>
        <TitleTxt>PRESIDENT AND CEO</TitleTxt>
        <BaseCompensationFilingOrgAmt>582000</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>143000</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>12337</DeferredCompensationFlngOrgAmt>
        <NontaxableBenefitsFilingOrgAmt>36378</NontaxableBenefitsFilingOrgAmt>
        <TotalCompensationFilingOrgAmt>773715</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>JULIA GREENSTEIN</PersonNm>
        <TitleTxt>VP RESEARCH</TitleTxt>
        <BaseCompensationFilingOrgAmt>264800</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>18000</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>12337</DeferredCompensationFlngOrgAmt>
        <NontaxableBenefitsFilingOrgAmt>2276</NontaxableBenefitsFilingOrgAmt>
        <TotalCompensationFilingOrgAmt>297413</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>AARON KOWALSKI</PersonNm>
        <TitleTxt>CHIEF MISSION OFFICER</TitleTxt>
        <BaseCompensationFilingOrgAmt>300000</BaseCompensationFilingOrgAmt>
        <BonusFilingOrganizationAmount>50000</BonusFilingOrganizationAmount>
        <DeferredCompensationFlngOrgAmt>7912</DeferredCompensationFlngOrgAmt>
        <NontaxableBenefitsFilingOrgAmt>27749</NontaxableBenefitsFilingOrgAmt>
        <TotalCompensationFilingOrgAmt>385661</TotalCompensationFilingOrgAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>SANDRA HIJIKATA</PersonNm>
        <TitleTxt>CHIEF DEV OFFICER &amp; ASST. SECY</TitleTxt>
        <BaseCompensationFilingOrgAmt>356333</BaseCompensationFilingOrgAmt>
        <OtherCompensationFilingOrgAmt>12000</OtherCompensationFilingOrgAmt>
        <DeferredCompensationFlngOrgAmt>12337</DeferredCompensationFlngOrgAmt>
        <NontaxableBenefitsFilingOrgAmt>5943</NontaxableBenefitsFilingOrgAmt>
        <TotalCompensationFilingOrgAmt>386613</TotalCompensationFilingOrgAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>MARK GREENE</PersonNm>
        <TitleTxt>CFO &amp; ASST. TRES</TitleTxt>
        <BaseCompensationFilingOrgAmt>345125</BaseCompensationFilingOrgAmt>
        <OtherCompensationFilingOrgAmt>18000</OtherCompensationFilingOrgAmt>
        <DeferredCompensationFlngOrgAmt>12337</DeferredCompensationFlngOrgAmt>
        <NontaxableBenefitsFilingOrgAmt>9951</NontaxableBenefitsFilingOrgAmt>
        <TotalCompensationFilingOrgAmt>385413</TotalCompensationFilingOrgAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>RICHARD INSEL ENDED 63016</PersonNm>
        <TitleTxt>CHIEF SCIENTIFIC OFFICER</TitleTxt>
        <BaseCompensationFilingOrgAmt>319352</BaseCompensationFilingOrgAmt>
        <OtherCompensationFilingOrgAmt>285750</OtherCompensationFilingOrgAmt>
        <DeferredCompensationFlngOrgAmt>12337</DeferredCompensationFlngOrgAmt>
        <NontaxableBenefitsFilingOrgAmt>15008</NontaxableBenefitsFilingOrgAmt>
        <TotalCompensationFilingOrgAmt>632447</TotalCompensationFilingOrgAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>JILL CLARK</PersonNm>
        <TitleTxt>CHIEF OF STAFF &amp; ASST. SECY</TitleTxt>
        <BaseCompensationFilingOrgAmt>227421</BaseCompensationFilingOrgAmt>
        <BonusFilingOrganizationAmount>9000</BonusFilingOrganizationAmount>
        <OtherCompensationFilingOrgAmt>4410</OtherCompensationFilingOrgAmt>
        <DeferredCompensationFlngOrgAmt>10828</DeferredCompensationFlngOrgAmt>
        <NontaxableBenefitsFilingOrgAmt>3875</NontaxableBenefitsFilingOrgAmt>
        <TotalCompensationFilingOrgAmt>255534</TotalCompensationFilingOrgAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>MARGO LUCERO</PersonNm>
        <TitleTxt>SVP CORPORATE DEVELOPMENT</TitleTxt>
        <BaseCompensationFilingOrgAmt>262640</BaseCompensationFilingOrgAmt>
        <OtherCompensationFilingOrgAmt>5360</OtherCompensationFilingOrgAmt>
        <DeferredCompensationFlngOrgAmt>12337</DeferredCompensationFlngOrgAmt>
        <NontaxableBenefitsFilingOrgAmt>25936</NontaxableBenefitsFilingOrgAmt>
        <TotalCompensationFilingOrgAmt>306273</TotalCompensationFilingOrgAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>STEVEN GRIFFEN MD</PersonNm>
        <TitleTxt>SVP RESEARCH</TitleTxt>
        <BaseCompensationFilingOrgAmt>376433</BaseCompensationFilingOrgAmt>
        <OtherCompensationFilingOrgAmt>600</OtherCompensationFilingOrgAmt>
        <DeferredCompensationFlngOrgAmt>12337</DeferredCompensationFlngOrgAmt>
        <NontaxableBenefitsFilingOrgAmt>30210</NontaxableBenefitsFilingOrgAmt>
        <TotalCompensationFilingOrgAmt>419580</TotalCompensationFilingOrgAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>JONATHAN R BEHR</PersonNm>
        <TitleTxt>MANAGING DIRECTOR JDRF-T1D FND</TitleTxt>
        <BaseCompensationFilingOrgAmt>25000</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>0</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>0</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>0</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>25000</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>HOUSING ALLOWANCE</FormAndLineReferenceDesc>
        <ExplanationTxt>SCHEDULE J PART I, LINE 1A Derek Rapp, Pres &amp; CEO, received a housing allowance as per the terms of his employment agreement. For the 2016 calendar year, the housing allowance provided to Derek Rapp was $75,000; such amount was treated as taxable compensation and included in his Form W-2. This amount was also reported on Schedule J, Part II, Col. (B) (III). Dr. Richard Insel, chief scientific officer, received a housing allowance as per the terms of his employment agreement. For the 2016 calendar year, the housing allowance provided to Dr. Insel was $25,000; such amount was treated as taxable compensation and included in his Form W-2. This amount was also reported on Schedule J,Part II, Col (B) (III).</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>OTHER REPORTABLE COMPENSATION</FormAndLineReferenceDesc>
        <ExplanationTxt>SCHEDULE J PART II, COL (B)(iii) DEREK RAPP RECEIVED TRAVEL &amp; ALLOWANCE EXPENSES FOR THE 2016 CALENDAR YEAR, THE ALLOWANCE PROVIDED TO MR. RAPP WAS $50,000; SUCH AMOUNT WAS TREATED AS TAXABLE COMPENSATION AND INCLUDED IN HIS FORM W-2. THIS AMOUNT WAS ALSO REPORTED ON SCHEDULE J, PART II, COL (B)(iii).</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>NON-FIXED PAYMENTS</FormAndLineReferenceDesc>
        <ExplanationTxt>FORM 990, SCHEDULE J, PART I, LINE 7 JDRF AWARDS NON-FIXED PAYMENTS SUCH AS BONUSES ON A DISCRETIONARY BASIS TIED TO THE EMPLOYEES PERFORMANCE. THE NAMES OF EMPLOYEES AND THE AMOUNTS THAT WERE PAID ARE FOUND ON SCHEDULE J, PAGE 2, PART II, COL. (B) (II).</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>SEVERANCE PAYMENTS</FormAndLineReferenceDesc>
        <ExplanationTxt>SCHEDULE J, PART I, LINE 4A DR. RICHARD INSEL RECEIVED A SEVERANCE PAYMENT OF $252,500 WHICH IS REPORTED ON SCHEDULE J, PART II, COL. (B)(III) OTHER REPORTABLE COMPENSATION.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleJ>
    <IRS990ScheduleL documentId="IRS990ScheduleL">
      <BusTrInvolveInterestedPrsnGrp>
        <NameOfInterested>
          <PersonNm>ELIZABETH KECKLER</PersonNm>
        </NameOfInterested>
        <RelationshipDescriptionTxt>DAUGHTER OF ELLEN LEAKE</RelationshipDescriptionTxt>
        <TransactionAmt>86773</TransactionAmt>
        <TransactionDesc>EMPLOYMENT AT JDRF INT.</TransactionDesc>
        <SharingOfRevenuesInd>false</SharingOfRevenuesInd>
      </BusTrInvolveInterestedPrsnGrp>
      <BusTrInvolveInterestedPrsnGrp>
        <NameOfInterested>
          <PersonNm>LINDSAY ALTMAN</PersonNm>
        </NameOfInterested>
        <RelationshipDescriptionTxt>DAUGHTER OF LISA ALTMAN</RelationshipDescriptionTxt>
        <TransactionAmt>22001</TransactionAmt>
        <TransactionDesc>EMPLOYMENT AT JDRF INT.</TransactionDesc>
        <SharingOfRevenuesInd>false</SharingOfRevenuesInd>
      </BusTrInvolveInterestedPrsnGrp>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>BUSINESS TRANSACTION</FormAndLineReferenceDesc>
        <ExplanationTxt>SCHEDULE L, PART IV, COLUMN B ELLEN LEAKE WAS THE BOARD VICE-CHAIR FOR YEAR END 6/30/2017 LISA ALTMAN WAS A JDRF BOARD MEMBER FOR YEAR END 6/30/2017 SCHEDULE L, PART IV, COLUMN C FOR EMPLOYEES LISTED, TOTAL COMPENSATION INCLUDES EMPLOYER PAID BENEFITS</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleL>
    <IRS990ScheduleM documentId="IRS990ScheduleM">
      <WorksOfArtGrp />
      <ArtHistoricalTreasuresGrp />
      <ArtFractionalInterestGrp />
      <BooksAndPublicationsGrp />
      <ClothingAndHouseholdGoodsGrp />
      <CarsAndOtherVehiclesGrp>
        <NonCashCheckboxInd>X</NonCashCheckboxInd>
        <ContributionCnt>8</ContributionCnt>
        <NoncashContributionsRptF990Amt>249790</NoncashContributionsRptF990Amt>
        <MethodOfDeterminingRevenuesTxt>TICKET SALES</MethodOfDeterminingRevenuesTxt>
      </CarsAndOtherVehiclesGrp>
      <BoatsAndPlanesGrp />
      <IntellectualPropertyGrp />
      <SecuritiesPubliclyTradedGrp>
        <NonCashCheckboxInd>X</NonCashCheckboxInd>
        <ContributionCnt>372</ContributionCnt>
        <NoncashContributionsRptF990Amt>4994790</NoncashContributionsRptF990Amt>
        <MethodOfDeterminingRevenuesTxt>NET PROCEEDS OF SALE</MethodOfDeterminingRevenuesTxt>
      </SecuritiesPubliclyTradedGrp>
      <SecuritiesCloselyHeldStockGrp />
      <SecurPrtnrshpTrustIntrstsGrp />
      <SecuritiesMiscellaneousGrp />
      <QualifiedContribHistStructGrp />
      <QualifiedContribOtherGrp />
      <RealEstateResidentialGrp />
      <RealEstateCommercialGrp />
      <RealEstateOtherGrp />
      <CollectiblesGrp />
      <FoodInventoryGrp />
      <DrugsAndMedicalSuppliesGrp />
      <TaxidermyGrp />
      <HistoricalArtifactsGrp />
      <ScientificSpecimensGrp />
      <ArchaeologicalArtifactsGrp />
      <OtherNonCashContriTableGrp>
        <NonCashCheckboxInd>X</NonCashCheckboxInd>
        <Desc>MISC AUCTION ITEMS DONATED</Desc>
        <ContributionCnt>27720</ContributionCnt>
        <NoncashContributionsRptF990Amt>11979668</NoncashContributionsRptF990Amt>
        <MethodOfDeterminingRevenuesTxt>FAIR MARKET VALUE</MethodOfDeterminingRevenuesTxt>
      </OtherNonCashContriTableGrp>
      <Form8283ReceivedCnt>1</Form8283ReceivedCnt>
      <AnyPropertyThatMustBeHeldInd>false</AnyPropertyThatMustBeHeldInd>
      <ReviewProcessUnusualNCGiftsInd>true</ReviewProcessUnusualNCGiftsInd>
      <ThirdPartiesUsedInd>true</ThirdPartiesUsedInd>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>THIRD PARTY ASSISTANCE</FormAndLineReferenceDesc>
        <ExplanationTxt>LINE 32B INSURANCE AUTO AUCTIONS LLC IS A THIRD PARTY CAR DONATION COMPANY THAT HANDLES ALL ASPECTS OF CARS BEING DONATED TO JDRF. DONORS CALL A TOLL FREE NUMBER AND THEY ARE PUT IN CONTACT WITH A TOWING SERVICE IN THEIR AREA. AFTER THE CAR IS DONATED, INSURANCE AUTO AUCTIONS HANDLES ALL IRS 1098-C REPORTING. INSURANCE AUTO AUCTIONS IS A LICENSED PROFESSIONAL FUNDRAISER AND IS LICENSED IN THE STATES THAT REQUIRE IT TO REGISTER. FOR THE PERIOD ENDING 6/30/17, THE CAR PROGRAM LLC RAISED $260,800 WITH TOTAL EXPENSES OF $95,118. A NET CHECK IS PAID DIRECTLY TO JDRF. JDRF DOES NOT PAY INSURANCE AUTO AUCTIONS ANY EXPENSES OR FEES DIRECTLY. TOTAL NET REVENUE FOR FY-17 WAS $165,682.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>NONCASH CONTRIBUTIONS</FormAndLineReferenceDesc>
        <ExplanationTxt>FORM 990, SCHEDULE M, PAGE 1 TYPES OF PROPERTY AND THE AMOUNTS LISTED IN PART I LINES 6, 9, and 25 ARE THE ACTUAL AMOUNT THAT DONORS HAVE DONATED FOR VEHICLES, SECURITIES, AND MISC ITEMS THAT ARE SOLD AT VARIOUS AUCTIONS &amp; RAFFLES.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleM>
    <IRS990ScheduleO documentId="IRS990ScheduleO">
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>ORGANIZATION'S MISSION</FormAndLineReferenceDesc>
        <ExplanationTxt>FORM 990, PART III, LINE 1 JDRFs mission is to accelerate life-changing breakthroughs to cure, prevent and treat Type 1 Diabetes (T1D) and its complications. JDRF is the leading global organization focused on T1D research and is committed to funding the development of new therapies and treatments to keep people with T1D healthier, longer, until a cure is found. Its strength lies in its exclusive focus and singular influence on the worldwide effort to end T1D. JDRF works every day to change the reality of this life-threatening autoimmune disease for millions of people - and to prevent anyone else from contracting the disease - by funding research, advocating for government support of research and new therapies, ensuring new therapies and technologies come to market, and connecting and engaging the T1D community. JDRF has funded more than $2 billion in research to date and made significant progress in understanding and fighting the disease. JDRF has played a role in nearly every T1D therapeutic advance of the past four decades, including the FDA-approved hybrid closed-loop artificial pancreas system in September 2016. PART III: STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS LINE 4A ($79,009,656) RESEARCH GRANTS JDRF funds research with the greatest potential to cure, prevent and treat type 1 diabetes (T1D). Its strength lies in its exclusive focus and singular influence on the worldwide effort to end T1D. JDRF has committed more than $2 billion to this research since 1970. The full impact of JDRFs research investment extends well beyond direct funding. JDRF leverages partnerships with academia, industry and clinicians to ensure that the most promising research opportunities are funded and accelerated. JDRF also provides early stage funding to research projects, and the results of those projects often lead to follow-on participation from many other entities, including other non-for-profit funders and corporations. JDRF's research team is staffed by accomplished experts and leaders in the field of T1D science and medicine who guide the organization's funding efforts. JDRFs highest priority remains funding research to deliver a cure for T1D and its complications. At the same time, JDRF is focused on developing better treatments that will transform the way people with T1D treat the disease today to help them live healthier lives now and in the future. The foundation's diversified research portfolio includes the following therapy areas: Artificial Pancreas: Artificial pancreas systems use technology to replicate the operation of a normal human pancreas and are one of the most revolutionary advances in diabetes care since the discovery of insulin. These systems link continuous glucose monitors and insulin pumps to smart software so that the right amount of insulin is delivered at the right time. Glucose Control: Glucose-responsive insulins (GRIs), or smart insulins, promise to be a game-changer in blood-sugar management. GRIs will be the first-ever insulin formulation that turns on and off in response to blood sugar highs and lows. JDRF is also funding research that explores the benefits of combining novel or repurposed drugs with standard insulin therapy. Beta Cell Replacement: This therapy, also known as encapsulation, can be implanted to provide long-term relief from insulin dosing without the need for immune suppression. JDRF-supported scientists are improving biomaterials for encapsulation devices to protect implanted beta cells from autoimmune attack, among other strategies. Beta Cell Restoration: This drug or biologic-based therapy represents a full biological cure for people with T1D. It stimulates restoration of the bodys own beta cells and the capacity to produce insulin. We are repurposing drugs that may reduce beta cell stress and/or induce survival, as well as funding immune therapies that will stop the disease in its tracks. Complications: JDRF-funded research has already yielded new treatments for diabetic eye and kidney disease, the most common complications. Today, researchers are identifying biomarkers and accelerating the completion of clinical trials of potential treatments. Prevention: JDRF research has identified a number of potential triggers, including viruses and environmental conditions, which could open the door to new vaccines and other prevention strategies. The organization is also funding efforts to stall the progression of the disease in those at risk or newly diagnosed. For more information, visit jdrf.org/research. The JDRF T1D Fund (www.t1dfund.org), a wholly owned subsidiary of JDRF, is a venture philanthropy fund accelerating life-changing solutions to treat, prevent and cure T1D through catalytic commercial investments. Through its investments in partnership with private capital, including venture capital, pharma and foundations, the T1D Fund seeks to attract the private investment necessary to advance drugs, devices, diagnostics, and vaccines into the hands of those living with T1D. The T1D Fund invests in whitespace opportunities and areas strategically aligned with JDRF, with an exclusive focus on the best commercial opportunities. All funds were deployed to directly support companies developing approaches to treat, prevent and cure T1D and are aligned with the JDRF mission. In accordance with GAAP, $7.1MM of the T1D Funds total investments for the FY17 period are reflected in the Balance Sheet (Part X) and not included within the organizations research-related mission expense. LINE 4B ($20,866,569) RESEARCH SUPPORT JDRF maintains an in-house team of skilled and credentialed scientific, policy and government relations professionals, each of whom plays a critical role in leading and supporting the research strategy and the disbursement of research funds from JDRF and others to create a world without type 1 diabetes (T1D). In their respective responsibilities, these professionals perform the functions of identifying, evaluating and influencing groundbreaking research being funded by JDRF, other foundations, governments and industry to achieve the organization's mission. These professionals also work with regulatory and policy officials to ensure research can proceed without delay and that research results are well understood by healthcare decision makers. As part of these efforts, JDRF organizes and funds scientific meetings, symposia, and conferences with the purpose of reviewing research proposals, ensuring that JDRF's research strategy is well aligned with the needs of the T1D community and allowing JDRF to provide scientific updates on the research it manages. JDRF also works with its external Research Advisory Committee (RAC), which is composed of professionals who are internationally renowned for their expertise in research as well as the care and treatment of those with T1D. The RAC advises on matters of policy pertaining to research philosophy and procedures to help the organization be most effective. All of this work to convene the best minds in the field enhances JDRF's ability to forecast future scientific direction, to judge the potential efficiency and effectiveness of new pathways and to identify gaps where JDRF can focus its funding to make the most impact. It is from this position of strength that JDRF identified opportunities where the Foundation can make significant advances in the near future and launched a five-year strategic plan in 2015 to accelerate progress to cure, prevent and treat T1D and its complications. LINE 4C ($52,763,561) PUBLIC EDUCATION Because of its leading role in type 1 diabetes (T1D) research globally, JDRF is in a unique position to provide public education about diabetes and its complications. JDRF's efforts impact not only the millions of people with the disease and their families and the general public, but also those at risk for developing the disease. Type 1 diabetes strikes both children and adults suddenly, and the adjustment period following a diagnosis can be overwhelming. JDRF educates people about the warning signs of T1D, which can be profoundly helpful in ensuring timely diagnoses and reducing the potential, short-term, catastrophic consequences of T1D. JDRF also provides information and updates about current research directions and progress and about human clinical trials that are seeking participants (including through JDRF's Clinical Trials Connection matching tool: www.jdrf.org/research/clinical-trials). Through all of its U.S. chapters and online, JDRF supports the T1D communitys diverse needs, connecting people with local support, expert resources and the worldwide effort to end this serious disease.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>CONFLICT OF INTEREST POLICY</FormAndLineReferenceDesc>
        <ExplanationTxt>FORM 990- PART VI-SECT B, LINE 12C All officers, directors, key employees, board and committee members (both chapters and international boards) are required to sign a conflict of interest policy annually and disclose any conflicts. The Office of the President and CEO manages this process, and JDRF's internal audit department annually audits to ensure compliance. If any conflict does arise, the board members with the conflicts will recuse themselves from the meeting and/or vote.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PUBLIC DOCUMENTS</FormAndLineReferenceDesc>
        <ExplanationTxt>FORM 990, PAGE 6, PART VI, SECTION C, LINE 19 The organization makes its governing documents, conflict of interest policy and financial statements available to the public on its website: www.JDRF.org. The public may access copies of JDRF's W-9, annual reports, 990 tax returns, 501(c)(3) IRS letter, and audited financials, at the following link: www.jdrf.org/about/financials</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>EXECUTIVE COMPENSATION POLICY</FormAndLineReferenceDesc>
        <ExplanationTxt>PART VI, SECTION B, LINES 15a &amp; 15b JDRFs Board of Directors charges a Talent and Compensation Committee to develop and recommend a compensation philosophy that applies to all employees of JDRF, including recommendations regarding the compensation and benefits of JDRF senior management for approval by the Executive Committee. The Committee works in collaboration with the President and CEO and the Chief People Officer and other senior staff personnel in the JDRF Human Resources Department to ensure that 1) the Foundations talent strategy supports and is aligned with its overall organization strategies; 2) JDRF is in compliance with IRS guidelines for determining reasonableness in pay practices; and 3) overall compensation for JDRFs key executives is competitive and aligned with pay philosophy. To attract and retain top scientific and executive talent to advance its mission, the organization pays competitive and appropriate salaries as determined by analysis of reliable data and input from independent third-party consultants. The review of JDRF executive compensation and benefits under the procedures noted above is completed annually by an independent Compensation Committee, and the basis for their determination are documented contemporaneously in the minutes of the Committees meetings, including most recently on November 10, 2016.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990 REVIEW PROCESS</FormAndLineReferenceDesc>
        <ExplanationTxt>SECTION B, PART VI, QUESTION 11B JDRF has a rigorous standard approach to reviewing its 990. The Organization's Tax Manager works with its outside tax professionals to prepare the return and all supporting schedules. The draft return is reviewed by a number of individuals, including JDRFs Chief Financial Officer and Director of Accounting and Finance, the Chief Executive Officer, other executives, its external senior tax advisor and others as necessary to ensure accuracy. Any questions and changes with respect to the draft return are addressed. Following this process, the return is reviewed by JDRFs Audit Committee of the Board of Directors with its outside tax advisors. Once approved, the return is distributed to all members of JDRFs Board of Directors for review and comment before it is filed with the Internal Revenue Service. KEY EMPLOYEE FORM 990, PART VII Jonathan R. Behr, Managing Director of the T1D Fund is a key employee of JDRF. The compensation reported on Part VII represents one month of calendar year 2016.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleO>
    <IRS990ScheduleR documentId="IRS990ScheduleR">
      <IdDisregardedEntitiesGrp>
        <DisregardedEntityName>
          <BusinessNameLine1Txt>JDRF T1D FUND LLC</BusinessNameLine1Txt>
        </DisregardedEntityName>
        <USAddress>
          <AddressLine1Txt>C/O JDRF - 26 BROADWAY 14TH FLOOR</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10004</ZIPCd>
        </USAddress>
        <EIN>274967989</EIN>
        <PrimaryActivitiesTxt>FUNDR/INVEST</PrimaryActivitiesTxt>
        <LegalDomicileStateCd>DE</LegalDomicileStateCd>
        <TotalIncomeAmt>12612251</TotalIncomeAmt>
        <EndOfYearAssetsAmt>23641793</EndOfYearAssetsAmt>
        <DirectControllingEntityName>
          <BusinessNameLine1Txt>JDRF</BusinessNameLine1Txt>
        </DirectControllingEntityName>
      </IdDisregardedEntitiesGrp>
      <IdRelatedOrgTxblCorpTrGrp>
        <RelatedOrganizationName>
          <BusinessNameLine1Txt>CHARITABLE REMAINDER TRUST (5)</BusinessNameLine1Txt>
        </RelatedOrganizationName>
        <PrimaryActivitiesTxt>ANNUITY</PrimaryActivitiesTxt>
        <LegalDomicileStateCd>PA</LegalDomicileStateCd>
        <ControlledOrganizationInd>true</ControlledOrganizationInd>
      </IdRelatedOrgTxblCorpTrGrp>
      <ReceiptOfIntAnntsRntsRyltsInd>false</ReceiptOfIntAnntsRntsRyltsInd>
      <GiftGrntOrCapContriToOthOrgInd>false</GiftGrntOrCapContriToOthOrgInd>
      <GiftGrntCapContriFromOthOrgInd>false</GiftGrntCapContriFromOthOrgInd>
      <LoansOrGuaranteesToOtherOrgInd>false</LoansOrGuaranteesToOtherOrgInd>
      <LoansOrGuaranteesFromOthOrgInd>false</LoansOrGuaranteesFromOthOrgInd>
      <DivRelatedOrganizationInd>false</DivRelatedOrganizationInd>
      <AssetSaleToOtherOrgInd>false</AssetSaleToOtherOrgInd>
      <AssetPurchaseFromOtherOrgInd>false</AssetPurchaseFromOtherOrgInd>
      <AssetExchangeInd>false</AssetExchangeInd>
      <RentalOfFacilitiesToOthOrgInd>false</RentalOfFacilitiesToOthOrgInd>
      <RentalOfFcltsFromOthOrgInd>false</RentalOfFcltsFromOthOrgInd>
      <PerformOfServicesForOthOrgInd>false</PerformOfServicesForOthOrgInd>
      <PerformOfServicesByOtherOrgInd>false</PerformOfServicesByOtherOrgInd>
      <SharingOfFacilitiesInd>false</SharingOfFacilitiesInd>
      <PaidEmployeesSharingInd>false</PaidEmployeesSharingInd>
      <ReimbursementPaidToOtherOrgInd>false</ReimbursementPaidToOtherOrgInd>
      <ReimbursementPaidByOtherOrgInd>false</ReimbursementPaidByOtherOrgInd>
      <TransferToOtherOrgInd>false</TransferToOtherOrgInd>
      <TransferFromOtherOrgInd>false</TransferFromOtherOrgInd>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>SCHEDULE R, PART I, LINE (1B)</FormAndLineReferenceDesc>
        <ExplanationTxt>THE PRIMARY ACTIVITY FOR THE JDRF T1D FUND IS FUNDRAISING AND INVESTING IN TYPE ONE DIABETES RESEARCH. PLEASE SEE DETAILED DESCRIPTION ON SCHEDULE O, PART III, LINE 4A, STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS FOR RESEARCH GRANTS.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleR>
  </ReturnData>
</Return>